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SUMMARY
SUMMARY
The studies reported in this thesis were designed to 
investigate the effects of chronic adrenoceptor drug 
treatment on central and peripheral alpha 2 ~adrenoceptor 
number in the rabbit. In addition, functional studies were 
carried out using the central depressor response to 
clonidine injection and vascular pressor response to bolus 
doses of alpha-methylnoradrenaline injection to examine 
central and peripheral responses, respectively. The effects 
of chronic adrenergic drug treatment on alpha- and beta- 
adrenoceptor number were examined in rabbit forebrain and 
hindbrain membranes and were compared with the effects in 
the periphery (kidney membranes) where appropriate. Also 
changes in receptor number were then compared with 
functional changes.
In preliminary experiments, it was observed that 
[^ H]yohimbine and [^H]idazoxan which have been described as 
alpha2 ~adrenoceptor ligands bind to the tissues used in 
these studies with different characteristics. This 
observation led to detailed examination and characterization 
of these binding sites (chapter three). The displacement of 
these ligands from their binding sites by a range of 
adrenergic drugs was exami n e d .  It was found that 
[H]yohimbine bound to alpha2 ~receptors while [ H]idazoxan 
in addition to binding at alph^-receptors bound principally 
to a non-adrenergic site.
In chapter four, the effects of chronic treatment with 
the alpha2 -adrenoceptor antagonists yohimbine and idazoxan
2
on alpha2 -adrenergic receptors were examined and compared 
with effects on the non-adrenergic site labelled by
“3
[ H] idazoxan. Functional changes occurring as a result of 
these treatments were also examined. Chronic yohimbine and 
idazoxan treatments significantly attenuated both vascular 
pressor responses to alpha-methylnoradrenaline bolus doses 
and the central depressor response to intracisternal 
clonidine. Yohimbine treatment significantly elevated
•3 . . .
[H]yohimbine binding to both forebrain and hindbrain but 
reduced [ H]idazoxan binding to kidney membranes with no 
change in the brain. Idazoxan treatment significantly
”3
increased [ H] yohimbine binding to the f o r e b r a m  and 
decreased [ H]idazoxan binding to the kidney.
In chapter five/ the effects of chronic amitriptyline 
treatment either alone or in combination with idazoxan or 
yohimbine on alpha 2 ~adrenergic and non-adrenergic binding 
sites along with effects on beta-adrenoceptor number were 
studied. Increasing catecholamine concentrations in the 
brain indirectly by chronic amitriptyline administration, 
significantly reduced [ H]yohimbine" binding to the hindbrain
•3 . . .
but not the forebram. [ H] Idazoxan binding sites were not 
significantly affected by this treatment. Neither treatment 
with amitriptyline alone nor when combined with alpha2“ 
adrenoceptor antagonists had any significant effects on the
-3 O
number of [ H ]dihydroalprenolol ([ H]DHA) binding sites.
Chapter six examined the effects of direct infusion of 
catecholamines i n t o  t h e  r a b b i t  b r a i n  v i a
3
intracerebroventricular infusion. Neither adrenaline nor 
noradrenaline had any significant effect on [ H]DHA or 
[H]yohimbine binding sites although chronic adrenaline 
but not noradrenaline infusion significantly attenuated the
depressor response to clonidine injection. Adrenaline
? . . infusion significantly reduced [ H]idazoxan binding to the
right cerebrum.
Chapter seven studied effects of chronic guanabenz 
infusion on b o t h  n u m b e r  and J u n c t i o n  of a l p h a 2 _ 
adrenoceptors. Chronic infusion with the alpha 2 - 
adrenoceptor agonist guanabenz significantly reduced 
[^H] yohimbine binding to both forebrain and hindbrain 
although no changes in kidney membranes were observed, while 
the number of [^H]idazoxan binding site in the kidney but 
not the forebrain or hindbrain was significantly reduced. 
Both the depressor and pressor responses to clonidine and 
alpha-methylnoradrenaline respectively were significantly 
attenuated by this treatment.
Chapter eight was aimed at bringing all the results in 
this thesis together, making comparisons, drawing 
conclusions and making proposals for future studies.
In this thesis it was observed that agonists can cause 
down regulation and antagonists up-regulation of the 
[^H] yohimbine binding site. Differences in regulation 
between tissues were observed which may have been due to 
differences in the alpha2 ~adrenoceptor subtype predominating 
in the tissues or differences in drug concentrations in 
different tissues. D o wn - r e gu 1 at i on was in g e n eral
4
accompanied by an attenuation of functional responses. In 
contrast, the [ H]idazoxan binding site was not regulated as 
expected, as no consistent changes were observed in brain 
although yohimbine, idazoxan and guanabenz all caused down 
regulation in the kidney. This differential regulation of
-3 . "3 . . .
the [H]yohimbine and [H]idazoxan binding sites further 
shows that they are different sites in the rabbit. The 
nature of the idazoxan binding site is yet to be understood 
and calls for studies looking at its function and the 
second messenger to which it is coupled. This will further 
the understanding of this binding site and help to unravel 
the complexity of alpha2 ~adrenoceptors and related sites.
Finally, no changes in beta-adrenoceptor number were 
observed in the rabbit brain during either catecholamine or 
amitriptyline treatments. This contrasts with observations 
in rat brain and reports of changes in beta-adrenoceptor 
number during catecholamine infusion into the periphery of 
rabbits. Small subtype changes may have occurred which were 
not detected, or alternatively, beta-adrenoceptors in rabbit 
brain are relatively resistant to down-regulation.
5
CHAPTER ONE
GENERAL INTRODUCTION
6
CHAPTER ONE
INTRODUCTION
1.1 HISTORY OF ADRENOCEPTOR CLASSIFICATION.
At the beginning of the century, a British physiologist 
Langley introduced the term "receptive substance" to 
describe the site at which chemical messengers might act. 
This also gave the key to the action of antagonists that 
might bind to the "receptive substance" and prevent the 
action of stimulant molecules (Langley, 1905).
Oliver and Shafer (1895) discovered that extracts from 
suprarenal gland induced a vasopressor effect. The active 
principle of this extract was identified as adrenaline and 
was later synthesized chemically (Stolz, 1904). The 
discovery of adrenaline led to the idea that sympathetic 
neurotransmission might be mediated by an adrenaline-like 
substance (Elliot, 1904). Early literature on this substance 
was greatly confused as a result of the the diverse effects 
that could be produced by exogenously applied adrenaline or 
its derivatives and also by adrenergic nerve stimulation. 
For example, it was proposed that either an inhibitory or 
excitatory substance ("sympathin I" and "sympathin E") could 
be liberated from adrenergic nerve endings on stimulation 
(Cannon and Rosenbluth, 1937; Greer et al., 1938; Gaddum and 
Goodwin, 1947). Dale (1906) building on the concept of 
"receptive substance" introduced by Langley, proposed the 
existence of subtypes of adrenergic receptors at myoneural 
junctions/ one of which he said mediated inhibitory effects
7
while the other mediated excitatory effects. This proposal 
was consequent to the differential effect of interaction 
of adrenaline and ergot alkaloids on smooth muscles.
Despite subsequent changes in methodology and
technology, the pharmacological tools that Dale and his 
colleagues (1906 and 1910) used as a means to differentiate 
receptors are still those that are used today; agonists, 
antagonists and structure-activity relationships.
Ahlquist ( 1 9 4 8 ) i n t r o d u c e d  the first f o r m a l
classification of adrenoceptors into alpha- and beta- 
adrenoceptors on the basis of the differring rank order of 
potency of a number of sympathomimetic amines in a variety 
of tissues. The function of these receptors were determined 
by e f f e c t s  of some c a t e c h o l a m i n e  on some a n i m a l
preparations. Where adrenaline appeared to be most potent 
and isoprenaline least potent, the receptor was classed as 
an alpha-adrenergic receptor. The alpha-adrenoceptor was 
shown to be linked with excitatory functions such as 
vasoconstriction and stimulation of smooth muscles (e.g. 
uterus and gastro-intestinal tract). At the beta-adrenergic 
receptor the order of potency was shown to be isoprenaline > 
adrenaline »  noradrenaline. Beta-adrenergic receptors were 
associated with inhibitory effects such as inhibition of 
uterine contraction, bronchial smooth muscles and 
vasodilation. It has also one excitatory function namely 
myocardial stimulation. The acceptance of the dual concept 
(alpha/beta) was slow, largely because of unavailability of 
subtype selective drugs. However, the discovery of
pharmacological agents and catecholamines (Moran and 
Perkins, 1958; Powell and Slater, 1958) altered this 
situation and in a short time a large number of tissue 
responses were designated alpha- or beta-adrenoceptor 
mediated effects on the basis of their selective blockade 
with alpha- or beta-adrenoceptor antagonists.
1.1.1 Beta-adrenoceptor subclassification.
By the mid 1960s Ahlquist's alpha/beta-adrenoceptor 
hypothesis was fairly well established. However careful 
quantitative studies and the introduction of further 
adrenoceptor agonists and antagonists suggested that a 
further subclassification of alpha- and beta-adrenoceptors 
was needed. Moran (1966) was the first to observe that beta- 
adrenoceptors were not of a homogeneous type in all tissues 
and proposed the subdivision of beta-adrenoceptors based on 
a differential tissue-dependent blockade of responses to 
isoprenaline by alpha-methylated derivatives of dichloro- 
isoprenaline and related compounds. This proposal was taken 
further by Furchgott (1959; 1967) and Lands et al., (1967) 
who subclassified beta-adrenoceptors into beta-^ and beta2- 
receptors. This subclassification was based on differences 
in the order of potencies of 12 agonists and antagonists in 
several isolated organ bath preparations.
The subdivision was validated and confirmed with the 
development and promotion of subtype selective antagonists
and agonists, practolol for beta-^-adrenoceptor (Dunlop and 
Shanks, 1968) and salbutamol for b e t a 2 ~adrenoceptors 
(Cullman et al., 1 969). At the beta-^-adrenoceptor, 
isoprenaline was found to have an efficacy greater than 
adrenaline = noradrenaline. The beta-^-adrenoceptor controls 
fatty acid mobilization, cardiac stimulation and inhibition 
of the contraction of rabbit small intestine. At beta2~ 
adrenoceptors, the relative potency was isoprenaline > 
adrenaline > noradrenaline. The beta2 -adrenoceptor controls 
inhibition of uterine contraction. With the development of 
subtype s e l e c t i v e  a g o n i s t s  and a n t a g o n i s t s ,  this 
classification has been further validated. It has been 
reported that the pharmacology- of beta^- and b e t a 2 - 
adrenoceptors are identical in all m a m m a l i a n  species 
(Minneman et al., 1981).
1.1.2 Alpha-adrenoceptor subclassification.
Unlike the beta-adrenoceptor where subclassification 
was relatively straightforward, identification of alpha- 
adrenoceptor subtypes was much more difficult. This was due 
in part to the more complex physiological responses elicited 
via alpha-adrenergic receptors and the lack of subtype 
selective drugs.
The first attempt at subclassifying alpha-adrenoceptor 
was based on anatomical location of the receptors with the 
suggestion that alpha-adrenergic receptors could be 
subdivided into postsynaptic and presynaptic subtypes
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(Langer, 1974). This subclassification was based on observed 
differences in the potency of phenoxybenzamine in inhibiting 
pre-synaptic t r a n s m i t t e r  r e l e a s e  and p o s t s y n a p t i c  
contractility of the cat spleen. The presynaptic alpha- 
adrenoceptors were shown to be involved in the regulation of 
transmitter release (e.g. noradrenaline) through the 
negative feedback mechanism mediated via stimulation by the 
transmitter itself (Langer, 1974; Starke, 1977), while 
postsynaptic alpha-adrenoceptors (postjunctional receptors) 
led to production of an effect (e.g. contraction of smooth 
muscles).
The p r e s y n a p t i c  a l p h a - a d r e n o c e p t o r s  c o uld be 
differentiated from the postsynaptic receptors using the 
relative activities of various agonists and antagonists 
(Langer, 1973; Starke, 1981). The postsynaptic receptor was 
classified as an alpha^-adrenoceptor with a relatively high 
affinity for the antagonist prazosin and the agonist 
methoxamine. The presynaptic alpha-adrenoceptor was 
classified as an alpha 2 -adrenoceptor and showed a high 
affinity for the a g o n i s t s  c l o n i d i n e  and alpha- 
methylnoradrenaline and the antagonists yohimbine (Starke, 
1977; Wikberg, 1979) and recently idazoxan (Doxey et al., 
1983).
While it a p p e a r s  that all p r e s y n a p t i c  alpha- 
adrenoceptor are of the alpha2 ~subtype there is now evidence 
for alpha 2 “adrenoceptors.outside noradrenergic terminal 
axons (Timmermans and Zwieten, 1982). Typical "presynaptic "
11
adrenoceptors have been demonstrated to be present on human 
platelets (Hoffman an Lefkowitz, 1980), cultured cells 
(Sabol and Nir e n b e r g ,  1 9 7 9), and frog skin, and 
postsynaptically, on smooth muscles (Pettinger, 1977; Digges 
and Summers, 1983). Hence, these observations impose 
limitations on the anatomical subclassification of alpha- 
adrenoceptor proposed by Langer, (1974).
As a result of the shortcomings of the anatomical 
classification of alpha-adrenoceptors, Berthelsen and 
Pettinger (1977) then proposed a functional basis for 
classification. Acco rding to their proposal, alpha^- and 
alpha2 ~adrenoceptors mediate excitatory and inhibitory 
responses, respectively.
The development and firm establishment of the concept 
of two distinct types of alpha-adrenoceptors has depended 
heavily on the availability of subtype selective drugs 
(Timmermans and van Zwieten, 1982). Currently,agonists as 
well as antagonists are available with a high degree of 
selectivity and specificity for either alpha-adrenoceptor 
subtype. The best definition for alpha^- versus alpha 2 - is 
based on the antagonists prazosin and yohimbine. Bylund 
(1981) and Bylund and U'Prichard (1983) have shown that at 
the alpha^-adrenoceptor site prazosin is more potent than 
yohimbine, while at the alpha2 ~adrenoceptor site yohimbine 
is more potent than prazosin. More recently idazoxan has 
also been shown to be more potent at alpha 2 ~ than alpha^- 
adrenoceptor sites (Dettmar et al., 1983; Doxey et al., 
1983) .
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1.1.3 Alphag-adrenoceptor heterogeneity.
Evidence has been emerging in the past few years 
indicating that neither alpha-^- nor alphag-adrenoceptors 
have identical characteristics in all tissues and species. 
These observed differences are much more pronounced in the 
case of alphag-adrenoceptor (Cheung et al., 1982; Bylund,
1985).
With the introduction of the alphag-adrenoceptor
antagonist yohimbine and its diastereoisomer rauwolscine as
[^H]ligands in the 1980s and [^H]clonidine earlier on
(Motulsky et al., 1980), evidence for the heterogeneity of
alphag-adrenergic binding sites has been mounting (Motulsky
et al., 1980; Cheung et al., 1982; Bylund, 1981; 1985).
Hoffman and Lefkowitz (1980), using the platelet as a model
system, developed a two state model for the alphag-
adrenergic receptor. This model showed agonists bind with
high affinity to the alphag-[H] but with low affinity to
alphag-[L] state, while antagonists bind both states with
equal affinity. Guanine nucleotides shift the equilibrium in
2 +favour of the alphag-[L] state whereas Mg favours the 
alphag-[H] state (Hoffman and Lefkowitz, 1980). On the basis 
of this model, one would expect that the number of 
[H]antagonists binding sites (Bmax) would either be greater 
than, or equal to, the number of binding sites for 
[ H]agonists. However, Bylund (1981) suggested the existence 
of alphag-adrenergic receptor subtypes after comparing the 
number of binding sites for [^H]yohimbine and [^H]clonidine
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in several tissues and species. He observed a considerable 
variation m  both the Bmax values for [ H]yohimbine and 
[ H]clonidine as well as the ratio between them. The Bmax
-3 . "3 t
ratio of [ H] yohimbine to [ H]clonidme for the rodents (rat 
and guinea pig) was consistently lower than the ratio for 
the non-rodents (cat and human) in all brain regions 
observed. He also observed that [ H] yohimbine has five to 
ten times higher affinity in the non-rodents than in 
rodents, that oxymetazoline is more potent in the non-rodent 
species and that prazosin is relatively more potent than 
yohimbine at alpha 2 ~adrenoceptors in rodents compared to 
non-rodents.
Using v a r i o u s  a d r e n e r g i c  agents to d i s p l a c e  
[^H]yohimbine and [^H]rauwolscine from rat cerebral cortex 
and human platelet membranes, Cheung et al. (1982) proposed 
the existence of alpha 2 -adrenoceptor heterogeneity. 
Alabaster et al. (1986) also made comparisions between 
alpha-adrenergic antagonist affinity for [JH] rauwolscine 
binding sites and observed wide variations between species 
and effects of drugs.
Bylund ( 1 9 85) and P e t r a s h  and B y l u n d  ( 1 9 8 6 ), 
demonstrated the existence of two population of alpha 2 ~ 
adrenoceptor sites in some regions of the human and rat 
brain. Based on the differences in their affinity for 
prazosin, these sites have been designated alpha 2 ^ and 
alpha2 B with the alpha 2 ^ having low affinity for 
prazosin (250 nM) . The alpha 2 ^ is predominantly found on 
human platelets. The alpha 2 B subtype has a high affinity
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for prazosin (5 nM), and neonatal rat lung is the prototype 
tissue for this subtype. Using differences in the 
radioligand binding between alpha2 ~adrenoceptors in kidney 
and platelet of the rabbit, Nahorski et al. (1985) proposed 
a similar definition for these subtypes (alpha 2 ^ and 
alpha2 g) . In addition, characterization of alpha 2 _ 
adrenoceptors on OK cells, a cell line derived from an 
Opossum kidney, led Murphy and Bylund (1988) to propose the 
existent of a third alpha 2 -adrenoceptor subtype. This 
receptor subtype was initially thought to be similar to the 
alpha2 B~subtype because of its high affinity for prazosin 
hence it was termed "alpha 2  B 1  ike" receptor. With more 
extensive characterization of the OK cell, it has been shown 
that this receptor is different from other alpha 2 - 
adrenoceptor subtypes and has been termed alpha 2 Q (Bylund, 
1988).
The successful cloning of the genes encoding alpha 2 _ 
adrenoceptors from human platelet and kidney by Kobilka et 
al. (1987) and Regan et al. (1988) have shown that the DNA 
sequences coding for the two receptors reside on different 
chromosomes. It was also reported that the two receptors 
have similar but unique primary amino acid sequences. The 
human platelet receptor was found to be derived from 
chromosome 1 0 , while the kidney receptor has its encoding 
gene on chromosome 4. These receptors were referred to as 
alpha2 ~C1 0  and a 1 ph a 2 “ C 4 , r e s p e c t i v e l y .  B a s e d  on 
pharmacological evidence and the correlation between data
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from the receptor expressed in COS-7 cells, platelet and 
HT29 cell, the alpha 2 ~C 1 0  receptor was identified as the 
alpha2 £~receptor. While the alpha2 ~C4 was identified as the 
alpha2 B-receptor. An indication for the existence of a third 
subtype of alpha2 ~adrenoceptor has been presented by Kobilka 
et al. (1987) when they found another receptor to reside on 
chromosome 2. This receptor has however not yet been cloned.
Boyajian and Leslie (1987) and Boyajian et al. (1987), 
using quantitative autoradiographic techniques have 
presented both anatomical and pharmacological evidence for
*3
differential binding and distribution of [H]rauwolscine and
*3 , . , . “
[ H] idazoxan binding sites within rat brain. It was not 
clear, however, to which subtypes of alpha2 -adrenoceptor the 
two ligands were binding.
1.1.4 Imidazoline binding sites.
Several i n v e s t i g a t o r s  have s u g g e s t e d  that the 
recognition sites of some alpha2 _adrenoceptor agonists with 
an i m i d a z o l i n e  m o i e t y  d i f f e r  fr o m  t h ose wi t h  a 
phenylethylamine-type structure (Ruffolo et al., 1977; Tayo, 
1979; Mottram, 1983; Mottram and Thakar, 1984; Bond et al.,
1986). Earlier Ruffolo et al. (1977) proposed that 
imidazolines i n t e r a c t  at sites other than a l p h a 2 - 
adrenoceptors w h e n  they f a i l e d  to o b s e r v e  a c r o s s ­
desensitization between the two compounds, imidazolines and 
phenylethylamines, on rat vas differentia preparations.
•3
Recently, several studies have shown [H]idazoxan and
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•3 . . . . .  . ,
[ H]para-aminoclon1 dine binding to non-adrenergic sites as 
well as alpha 2 ~adrenergic receptors in rabbit kidney and 
guinea pig brain tissues (Ernsberger et al., 1988; Lachaud 
et al., 1988; Wikberg 1988). However, it is not known if 
these non-adrenergic sites which have been referred to as 
imidazol (in) e, i d a z o x a n  or c l o n i d i n e  b i n d i n g  sites 
(Yablonsky et al., 1988; Ernsberger et al., 1986; Wikberg, 
1988) are a homogeneous receptor site.
Clonidine has r e c e n t l y  b e e n  s h o w n  to b i n d  
preferentially to imidazoline binding sites as well as 
alpha2 _adrenoceptors in the ventrolateral medulla from 
bovine brain (Ernsberger et al., 1986) and a low molecular 
weight substance has been isolated from both bovine and rat 
brain membranes (Atlas and Burstein, 1984; Meeley et al.,
1986). This substance has been shown to potently displace
o o
[ H] clonidine and its analogue [JH]para-aminoclondme from 
their binding sites in bovine ventrolateral medulla 
membranes with a higher affinity for non-adrenergic sites 
(Atlas and Burtein, 1 984; Meeley et al., 1 9 8 6 ). The 
substance has been named clonidine displacing substance 
(CDS) (Meeley et al., 1 98 6 ; Fel-sen et al., 1 987). The 
isolated clonidine displacing substance has been shown to be 
biologically active. Bousquet et al. (1986) and Meeley et 
al. (1986) have shown that rostral ventrolateral medulla 
injection of CDS in rats or cats modifies arterial blood 
pressure. It has also been reported to potently contract rat 
gastric fundus (Felsen et al., 1987) and block electrically
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stimulated contraction of rat vas deferens (Diamant and 
Atlas, 1986).
1.1.5 Alphag-adrenoceptor heterogeneity.
Variation has also been observed in the pharmacological 
properties of alpha^-adrenoceptors in different tissues and 
species and this has led to speculation on the existence of 
more than one alphag-adrenoceptor subtype (Drew and Whiting, 
1979; McGrath, 1982). Flavahan and Vanhoute (1986) have also 
suggested the existence of two subtypes of alphag- 
adrenoceptor after analysing the pA 2 (affinity) values of 
prazosin and yohimbine on alphag-adrenoceptor contractile 
responses in blood vessels from rodents and rabbits. They 
observed that one of the subtypes of this receptor has a 
higher affinity for prazosin than yohimbine while the other 
has low affinity for these alpha-adrenoceptor antagonists. 
As a result of the differences observed in the affinities of 
clonidine and yohimbine for aortic vessels from six 
different species, Ruffolo and Waddel (1982) had earlier 
proposed the existence of alphag-adrenoceptor subtypes. 
Based on the actions of indanidine and phenoxybenzamine, 
Coats et al. (1982) also proposed the existent of a subtype 
(alpha^S) w h i c h  they said was a subset of alph a ^ -  
adrenoceptors. In this experiment, the alpha^S was shown to 
be activated by indanidine and to be particularly sensitive 
to phenoxybenzamine, while the classical alphag-adrenoceptor 
was defined as one where noradrenaline but not indanidine
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was active. In order to explain the differential effects 
(potency) of imidazolines and phenylethylamines, McGrath 
(1982) proposed two subtypes (alpha^a and alpha^b) . He 
noticed that imidazolines and phenylethylamines were highly 
potent in some tissues which he called alpha^a, while 
imidazolines were not effective in the remaining tissues 
which he referred to as alpha^b.
Recently, Han et al. (1987) have provided evidence for 
the existence of alpha-^a and alpha-j_b-subtypes in which 
functional responses at the second messenger level were 
incorporated in their definition. In their experiments, they 
noticed that rat vas deferens contains two subpopulations of 
alpha-^-adrenoceptors (alpha^a and alpha^b), each subtype
O
having a different function in coupling Ca release by 
neurotransmitters and hormones.
Table 1.1 s h o w s  t h e  p r o p o s e d  a d r e n o c e p t o r  
classification.
1.1.6 Radioligand binding studies of adrenergic 
receptors.
The introduction of direct radioligand binding studies 
has changed the entire complexion of the experimental 
approach to the study and understanding of adrenergic 
receptors and the events they mediate. Radioligands have 
made much more accurate quantification of adrenergic 
receptors possible and have increased our understanding of
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-PROPOSED CLASSIFICATION OF ADRENOCEPTORS
Adrenoceptors
j3—Adrenoceptor
coupled to G s
0 i 0 :
(2 —Adrenoceptor CX~ Adrenoceptor
coupled to G, coupled to G
a 2a a 2b a 2c a 1a a1b
Table 1.1
Proposed classification of adrenoceptors.
(Adapted from Bylund, 1988).
Gs = Stimulatory guanine nucleotide binding protein,
Gi = Inhibitory guanine nucleotide binding protein,
Gx = Guanine nucleotide binding protein not yet 
characterized.
2 0
drug-receptor interactions.
The first ligands employed in radioligand binding
r> , . . .
experiments were the [ H]catecholamines, but this pioneering
effort met with limited success be-cause of the low specific
activity and the high non-specific binding of these ligands
(U'Prichard and Snyder, 1977; Davies and Lefkowitz, 1981).
Successful radioligand binding was first reported for beta­
's
adrenergic r e c e p t o r s  u s i n g  [ H] a l p r e n o l o l  and
o o
[ H] dihydroalprenolol, while [ H] dihydroergocryptme and 
[^H]clonidine were used for alpha-adrenoceptors (Aurbach et 
al., 1974; Levitzki et al., 1974; Lefkowitz et al., 1974; 
Williams and Lefkowitz, 1976; Greenberg and Snyder, 1977).
Several radioligands with high affinity have been 
developed and used to study beta- and alpha-adrenergic 
receptors in a variety of tissue systems. These include 
[^H] dihydroalprenolol, iodohydroxybenzylpindolol,
[^ H]hydroxybenzylisoproterenol (Hoffman and Lefkowitz, 1980) 
and recently [ ^ ^ 1  ] iodocyanopindolol (ICYP) (Brodde et al., 
1981) for b e t a - a d renoceptors. While ligands such as 
[ ^ H] dihydroergocrypt ine ( [  ^H ] D H E ) , [^H] W B 4 1 0 1 ,
[^H]clonidine, [^H]epinephrine (Hoffman and Lefkowitz, 1980) 
and recently [^H]yohimbine and [^H]idazoxan (Motulsky et 
al., 1980; Covents et al., 1987) have been used to study 
alpha-adrenergic receptors. This has led to a variety of 
different binding patterns. These different patterns may 
relate to heterogeneity of alpha-adrenergic receptors and 
the varying regulatory properties of these receptors
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(Hoffman and Lefkowitz, 1980; Motulsky et al., 1980; Bylund, 
1985) .
In a d d i t i o n  to b i n d i n g  to s p e c i f i c  r e c e p t o r s  
radioligands may bind at other sites. For radioligand 
binding sites to be recognised as functional receptors, 
criteria were set first by Cuatracesas (1974) and recently 
by Motulsky and Insel (1984). These conditions have to be 
satisfied to demonstrate that radioligand binding sites may 
be equated with receptor sites. These conditions as defined 
by Motulsky and Insel (1984) are as follows:-
i) Stereospecific criteria must be satisfied. Where
stereoisomerism has biological relevance as in the
catecholamines the r e c e p t o r  mu s t  be ster e o -  
specific i.e -isomers more potent than +isomers.
ii) The affinity of the binding site and kinetic rate 
constants of binding should correlate with the
biological properties of the ligand used in 
binding studies.
iii) Specific binding should be saturable and
proportional to tissue concentration.
iv) Binding should be as rapid and reversible as are the
physiological responses to the ligand.
v) Unlabelled ligands should compete for radioligand 
binding sites with similar relative potencies as 
those obtained from pharmacological experiments.
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vi) Radioligands should remain unaltered throughout the 
course of the experiment.
vii) Alternative methods should give approximately 
identical values for the parameters (equilibrium 
dissociation (KD) constant and maximum number of 
binding sites (Bmax) ) .
These criteria are necessary but may not be sufficient 
for identifying a receptor since transport systems for a 
hormone may satisfy all these criteria and yet may not be 
physiologically relevant receptor sites.
However, the basic principles of this technique entails 
incubation of a tissue homogenate with a tritiated or 
iodinated form of an adrenergic agonist or antagonist in the 
presence or absence of a non-labelled displacing drug. 
Commonly used displacing agents include prazosin for alpha-^- 
, yohimbine for alpha2 ~A practolol for beta-j_- and metoprolol 
for beta 2 _receptors. Specific binding is defined as the 
difference between radioactivity observed in the absence of 
unlabelled ligand (total binding) and that in the presence 
(non-specific binding). The specific binding should approach 
a maximum (Bmax) in a saturable manner. The concentration 
of ligand that binds to half of these receptors is the 
dissociation constant (KD) . These parameters are obtained 
from the analysis of the Scatchard or other suitable plots 
(Scatchard 1947).
In contrast to specific binding sites which are finite
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and saturable, it is assumed that non-specific binding sites 
are effectively infinite.
1.2 BIOCHEMICAL MECHANISMS OF SIGNAL TRANSDUCTION.
Many extracellular signals (first messengers), such as 
neurotransmitters, hormones and growth factors, do not 
permeate the plasma membrane. Instead, they interact with 
the recognition sites (receptors) at the cell surface, which 
via a series of events finally leads to a physiological 
response in the form of contraction, relaxation, secretion, 
inhibition, or growth, etc. The processes linking receptor 
activation to intracellular events is known as transduction 
and was first used to describe the transfer of information 
between the receptors for a variety of hormones and 
adenylate cyclase, the enzyme responsible for the production 
of cyclic adenosine monophosphate (cAMP) (Rodbell et al., 
1969) . Adenylate cyclase and other systems that relay 
messages from the exterior are collectively referred to as 
"second messengers".
As a model for information transfer, a tripartite model 
has been suggested (Rodbell, 1980). This model is composed 
of recognition, transduction, and effector or amplifying 
components (fig. 1.1). Recognition is represented by the 
surface receptor, transduction involves members of a family 
of guanine nucleotide-binding regulatory proteins (G- 
proteins) and effector or amplifying component such as cyclic
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Figure 1.1
Components of transmembrane signalling and processes 
involved in adenylate cyclase activation.
(Adapted from Rodbell/ 1980).
Receptor (R), Guanine nucleotide protein (Gs), Adenylate 
cyclase (AC), Guanosine triphosphate (GTP), Adenosine 
triphosphate (ATP), Guanosine diphosphate (GDP), Cyclic 
adenosine monophosphate (cAMP).
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AMP. Decades of research have led to the understanding that 
these steps are carried out by distinct macromolecular 
components.
1.2.1 Beta-adrenoceptor effector coupling.
Sutherland a n d  Rail, (1960) d i s c o v e r e d  t h a t  
catecholamines and sympathomimetic agents acting via beta- 
adrenoceptors transmit their messages to the cell interior 
by stimulating the synthesis of cyclic adenosine 
monophosphate (cAMP) an intracellular nucleotide "second 
messenger" that is present at micromolar concentrations. 
Cyclic AMP is one of the most intensively investigated 
second messengers (Ross and Gilman, 1980).
Binding of the agonist to the receptor (R) leads to a 
conformational change in the receptor molecule (R'), the 
complex (agonist-R') formed then binds to the guanine 
nucleotide (Gs) protein to form a transient agonist-R'-G 
ternary complex. The formation of this complex facilitates 
the conversion of GTP to GDP by ATPase, and this causes the 
dissociation of the Gs-protein from the agonist-R'complex. 
The G-protein then binds to and activates adenylate cyclase 
(AC) (figure 1.1). The activation of adenylate cyclase leads 
to the conversion of adenosine triphosphate (ATP) to 
adenosine-3-5-monophosphate (cAMP) which serves as "second 
messenger" and activates intracellular protein kinases. 
These in turn cause phosphorylation of enzymes that lead to 
the cellular response such as smooth muscle relaxation
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glycolysis, lipolysis, etc.
In radioligand binding studies, agonist and antagonist 
binding characteristics differ (Lefkowitz et al., 1983). 
The inhibition of radioligand antagonist binding by 
unlabelled antagonist follows simple Mass Action kinetics 
(Kent et al., 1980). The slope of antagonist competition 
curves are steep w i t h  Hill c o e f f i c i e n t s  that are 
approximately equal to one. Analysis of the curves indicate 
that antagonists bind to a single receptor affinity state 
(Kent et al., 1980). In contrast, antagonist radioligand 
binding inhibition by agonists results in competition curves 
with "shallow” slopes and Hill coefficients of less than one 
(De Lean et al., 1980), which is consistent with the agonist 
binding to more than one affinity state of the receptor 
(Kent et al., 1980). These " s hallow" curves are 
characteristic of agonists competing against labelled 
antagonist ligands. The ability of agonists to promote the 
formation of a receptor-G-protein complex corresponds to the 
ability of the agonist to form a high affinity state of 
receptor. The binding of guanosine triphosphate (GTP) to the 
ternary complex initiates two events, one is to destabilise 
the ternary complex so that the receptor returns to its low 
affinity state (HR) . This explains the GTP induced decrease 
in apparent affinity for agonists and the steepening of the 
agonist competition displacement curve so that agonists in 
the presence of GTP appear to interact with a single state 
of the receptor (lower affinity state) (Nahorski and
27
Barnett, 1 982; Motulsky and Insel, 1 982). A second 
simultaneous consequence of GTP binding to agonist-receptor- 
G-protein complex is activation of the G-protein (probably 
by a conformational change) (Bottari et al., 1979). The 
activated G-protein-GTP complex then activates the catalytic 
moiety of adenylate cyclase (Stadel et al., 1981).
So far, at least three G-proteins have been suggested 
to exist. Of these, two have been widely studied, Gs- and 
Gi- which have been shown to have stimulatory and inhibitory 
actions respectively (Rodbell, 1980). Gs and Gi can be 
distinguished by cholera and pertusis toxins. Gs is 
inhibited by cholera toxin and Gi by pertusis toxin. The 
third type which has not been extensively studied has been 
postulated to regulate membrane processes other than 
adenylate cyclase and is referred to as the Gx-protein 
(Rodbell, 1980). It is not inhibited by either cholera toxin 
or pertusis toxin. The G-proteins consist of 3 subunits 
(alpha, beta and gamma) . The beta and gamma subunits are 
conserved in all types of G-proteins while the alpha subunit 
differs.
1.2.2 Alpha2-adrenoceptor effector-coupling.
Like the beta-adrenoceptors, alpha 2 -adrenoceptors are 
coupled to adenylate cyclase but unlike the beta- 
adrenoceptors, activation of alpha 2 _receptors leads to 
inhibition of cAMP production, since they are negatively 
coupled to adenylate cyclase (Fain and Garcia-Sainz, 1980).
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However, little information is available in the literature 
on hormonal activation of alpha 2 -adrenoceptors and its 
coupling to the s e c o n d  m e s s e n g e r .  As for beta- 
adrenoceptors, agonists bind to two affinity states (high 
and low) at the alpha 2 -adrenoceptor, while antagonists 
recognise a single affinity state (Bylund and U'Prichard, 
1983; Nahorski et al., 1985). Adenylate cyclase inhibition 
occurs through activation of a different guanine nucleotide 
binding protein (Gi) which is distinct from the one 
responsible for stimulation (Gs) (Jakobs et al., 1984; 
Jakobs, 1985). Jakobs and Schultz (1983), have reported a 
decrease in cAMP levels in platelets, hepatocytes, cerebral 
microblastoma cells on alpha 2 -adrenoceptor stimulation. 
However, opinions are divided on the mechanisms by which 
this guanine nucleotide protein causes a decrease in 
adenylate cyclase activity. Both direct mechanisms via the 
beta, g a m m a  s u b u n i t s  and i n d i r e c t  m e c h a n i s m s  via 
phospholipase A or Na+/H+ exchange have been postulated.
1.2.3 Alphag-adrenoceptor effector coupling.
In contrast to alpha2 ~ and beta-adrenoceptors, alpha-^- 
adrenoceptors do not transmit their signal to the cell 
interior via cAMP.
Agonist binding to alphag-adrenoceptor activates 
membrane bound phospholipase C an enzyme that catalyses the 
hydrolysis of phosphatidylinositol-4,5-bisphosphate (PIP2 )
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to myoinositol-1,4,5-trisphosphate - (IP3 ) and diacylglycerol
(DG) (Homey and Graham, 1975; Michell 1983; 1985; Berridge
1984). The inositol-1, 4,5-trisphosphate produced then
9 +activates the release of Ca from intracellular stores into 
the cytosol (Streb et al., 1983). This can in turn activate 
cellular responses such as actin-myosin coupling and hence 
tissue/muscle contraction (Michell, 1985) (figure 1.2). The
location of the inositol-1, 4,5-trisphosphate sensitive
9 + . .Ca pool is uncertain, but it may be m  some element of the
endoplasmic reticulum membrane system.
1,2-Diacylglycerol (1,2-DG), the other product of
Ptdins-4,5-bisphosphate (PIP2 ) breakdown is the first
conclusively identified membrane associated "second
messenger" molecule; it activates a novel phospholipid- and 
9 +Ca dependent protein kinase known as protein kinase C
(Nishizuka, 1983). Among other actions, protein kinase C may
influence the influx of extracellular calcium. Thus the
9 4-mobilization of Ca from intracellular vesicles and the
9 +influx of extracellular Ca appears to be linked to the 
activation of the alphag-adrenoceptor.
Figure 1.2 shows a diagramatic representation of some 
of the mechanisms of transmembrane signalling used by cell 
surface receptors.
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Figure 1.2
Mechanisms of transmembrane signalling used by cell 
adrenergic receptors. (Adapted from Michell, 1987).
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1.3 ADRENERGIC RECEPTOR REGULATION.
The phenomenon of denervation supersensitivty and drug 
tachyphylaxis have intrigued pharmacologists for many years. 
It is now possible to investigate the molecular mechanisms 
involved in this regulatory pro'cess using radioligand 
binding techniques. Receptor regulation refers to the 
processes that modify an agents ability to bind to a 
receptor and induce an effect. After a cell or tissue has 
been exposed for a period of time to an agonist or hormone 
such as a catecholamine, that tissue often becomes less 
responsive to further stimulation by that particular agent. 
A variety of terms have been employed to describe such 
processes i n c l u d i n g  t o l e r a n c e ,  d e s e n s i t i z a t i o n , 
refractoriness and tachyphylaxis. This phenomenon has 
clearly been demonstrated for at least some beta-adrenergic 
and alpha-adrenergic responses (Davies and Lefkowitz, 1981; 
1984) . The regulation of adrenergic effects may involve 
changes in receptor number or affinity, altered coupling of 
the receptor to adenylate cyclase or other effector 
mechanisms, and may be demonstrable in a variety of 
experimental conditions e.g. intact animals, whole cell 
suspensions or isolated membrane preparations (Brodde et 
al., 1982; Harden, 1983; Insel and Motulsky, 1987).
It s h o u l d  be n o t e d  that d o w n  r e g u l a t i o n  and 
desensitization are not synonymous; down regulation refers 
to a fall in receptor number while desensitization refers to 
a reduction in biological responses to a hormone or agonist
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stimulus. A receptor system may be down regulated or 
desensitized but not necessarily both. Similarly, up- 
regulation and supersensitization are not synonymous.
Desensitization phenomenon have been classified into 
two broad categories, agonist-specific or "homologous" and 
agonist non-specific or "heterologous". Homologous 
desensitization refers to the form of regulation where, 
after exposure to an agonist for some time, the cell becomes 
refractory to a further stimulation specifically by that 
agonist, while actions of other agents or hormones remain 
unaffected. Conversely, heterologous, or agonist non­
specific desensitization indicates that exposure of a 
receptor system to an agonist leads to attenuation of the 
response to other agonists operating through distinct 
receptors (Hertel and Perkins, 1984; Davies and Lefkowitz, 
1981; Sibley et al., 1987). It has been proposed that these 
two processes occur by distinct mechanisms. The detailed 
processes responsible for these receptor alterations are 
however not known at present.
1.3.1 Desensitization and down regulation of beta- 
adrenergic receptors.
Desensitization has been extensively studied for the 
beta-adrenoceptor coupled adenylate-cyclase system (Harden, 
1983; Hertel and Perkins, 1984; Sibley and Lefkowitz, 1985). 
Long term exposure of responsive cells to a beta-adrenergic 
agonist leads to a rapid loss in agonist-stimulated
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adenylate cyclase activity.
The mode of loss of receptor sensitivity after chronic 
stimulation by agonists or hormones occurs in stages. The 
first stage involves the uncoupling of receptors from 
adenylate cyclase within the plasma membrane without any 
loss of beta-adrenergic receptors as measured by binding of
*3
hydrophobic antagonists such as [ H]dihydroalprenolol or 
[125j] -labelled pindolol. It is believed that there are 
alterations in the conformational state of the receptor so 
that it is unable to activate adenylate cyclase. The process 
is rapid and involves conversion of the receptor from a high 
to a low affinity state which occurs within 1 - 2  minutes 
(Harden et al., 1979; Su et al., 1979; 1980; Homburger et 
al., 1980).
The process of beta-adrenaceptor uncoupling also
involves the Gs-protein. The uncoupling process is rapidly
followed by sequestration of the uncoupled receptor into
vesicles away from the cell surface (Staehelin and Simonis,
1982; Stadel et al., 1983). The receptors are therefore said
to be internalized and become less accessible to hydrophobic
3agonist and antagonist binding ligands such as [^HICGP- 
12177. Further evidence for redistribution of receptors was 
observed from differential centrifugation. When cell lysates 
or homogenates were analysed by sucrose density gradient 
centrifugation, it was noted that some of the receptors were 
shifted from plasma membrane to a light vesicle fraction 
which sediments at higher centrifugal forces (Fishman and
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Perkins, 1988). With the loss of antagonist binding sites at 
the cell surface, there was at the same time an appearance 
of [ H]dihydroalprenolol binding sites m  the soluble 
fraction of the disrupted cells. This observation led to the 
hypothesis that agonist modified receptors are redistributed 
in the cytosol (Davies and Lefkowitz, 1981; Staehelin et 
al., 1 983; Mahan et al., 1 985). This might well be 
compatible with an internalization mechanism. Redistribution 
only appears to involve physical separation of beta- 
adrenergic receptor from Gs-protein. The redistributed 
receptors can still be quantified by conventional antagonist 
radioligand binding techniques which label total receptor 
populations.
Homologous desensitization of beta-adrenergic receptors 
appears to involve phosphorylation of the receptor by a 
novel protein kinase which is independent of cAMP. The 
enzyme termed beta-adrenergic receptor kinase (BARK) is 
common in mammalian tissues and appears to be cytosolic 
(Benovic et al., 1986; Strasser et al., 1986). The BARK is 
specific for beta-adrenergic receptors and possibly other 
receptors which are coupled to adenylate-cyclase. It has a 
unique property of phosphorylating only the agonist-occupied 
form of the receptor, the antagonist occupied or unoccupied 
receptor is not a substrate (Strasser et al., 1986; Sibley 
et al., 1987; Lefkowitz and Caron, 1988). This type of 
phosphorylation reaction can therefore be described as 
substrate-activated rather than kinase-activated. Agonist 
occupation of the receptor leads to translocation of beta-
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adrenergic receptor kinase from the cytosol to the plasma 
membrane where it phosphorylates the agonist occupied 
receptor (Strasser et al., 1986; Sibley et al., 1987). This 
is followed by functional uncoupling of the receptors from 
adenylate-cyclase. The receptors then become sequestered or 
internalized into low density membrane particles or 
vesicles. The nature of this internalized compartment and 
the mechanisms by which receptor translocation occur are not 
yet understood. The internalized receptors may be 
dephosphorylated and functionally redistributed to the cell 
surface. A reduction in agonist concentration or its removal 
may lead to receptor redistribution to basal levels. However 
prolonged agonist stimulation will result in more receptors 
being internalized for longer and could lead to receptor 
degradation and loss which can cause the reduction in total 
receptor number, usually referred to as down-regulation.
It has been speculated that all adenylate-cyclase 
coupled r e c e p t o r s  s h a r e  a c o m m o n  d o m a i n  w h e r e  
phosphorylation by BARK takes place and that this domain is 
exposed on occupation of the receptor. Agonist-occupied 
receptors are substrates for the enzyme while uncoupled 
receptors will escape desensitization. Figure 1.3 presents 
molecular events which may be involved in homologous 
desensitization of beta-adrenergic receptors.
Mechanisms of heterologous desensitization of beta- 
adrenergic receptors are said to involve phosphorylation of 
the receptors by cAMP-dependent protein kinases (protein
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kinases A and C). Activation of adenylate cyclase by any of 
several hormones leads to increased concentrations of cAMP, 
protein kinases become activated and the beta-adrenergic 
receptor is phosphorylated. Evidence for this mechanism of 
regulation of beta-adrenoceptors comes from studies with 
avian erythrocytes, which present a close correlation 
between catecholamine-induced heterologous desensitization 
and beta-adrenergic phosphorylation (Stadel et al., 1983; 
Nambi et al., 1985). Phosphorylation of beta-adrenergic 
receptors in vitro by both protein kinase A and C has also 
been reported (Benovic et al., 1986; Bouvier et al., 1987). 
The rate but not the extent of the reaction is enhanced by 
agonist occupation of the receptor. Phosphorylation reduces 
the ability of the agonist-occupied receptor to stimulate 
the GTPase activity of this coupled Gs-protein, hence it 
appears to be a functionally significant modification. Since 
any hormone or drug that increases cAMP levels will 
presumably lead to phosphorylation, this type of regulatory 
mechanism is referred to as heterologous. Receptor 
phosphorylation and desensitization has been reported after 
treatment of intact cells with phorbol esters, which can 
directly activate protein kinase C (Kelleher et al., 1984; 
Sibley et al., 1987; Lefkowitz and Caron, 1988). Activation 
of protein kinase C by phosphatidylinositol (PI) hydrolysis 
may also promote heterologous desehsitization.
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Figure 1.3
Molecular mechanisms involved in homologous desensitization 
of beta-adrenoceptors. (Adapted from Lefkowitz and Caron, 
1988) .
BAR = Beta-adrenoceptor
Ns = Nucleotide stimulatory protein
C = Adenylate cyclase
BARK = Beta-adrenoceptor kinase
P04 = Phosphate
38
1.3.2 Desensitization and down-regulation of alpha-
adrenergic receptors.
The mechanisms involved in the desensitization 
processes described have been entirely derived from studies 
of beta-adrenergic receptor responses. Unlike beta- 
adrenoceptors, the regulation of alpha-adrenergic receptor 
mediated responses have been much less explored. The lack of 
understanding of the mechanisms of action of alpha- 
adrenoceptors c o u p l e d  w i t h  the a b s e n c e  of s u i t a b l e  
hydrophilic radioligands, might partly be responsible for 
the lack of information on the regulation of the alphag- 
adrenergic receptor system which is negatively coupled to 
adenylate cyclase.
1.3.2.1 Mechanisms of alphag-adrenoceptor 
desensitization.
Alphag-adrenoceptors are n e g a t i v e l y  c o u p l e d  to 
adenylate cyclase via the inhibitory guanine nucleotide 
binding protein (Gi). The mechanism of desensitization of 
alphag-adrenoceptors has been much less studied. Much 
information on alphag-adrenoceptor coupling and p o s t ­
receptor mechanisms has come from studies using platelets 
(Motulsky et al., 1986; Insel and Motulsky, 1987). Despite 
their usefulness for such studies, platelets, unlike most 
cells, lack nuclei and are deficient in protein synthesis. 
Hence, for more understanding of the metabolism and cellular
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dynamics of alpha 2 ~adrenoceptors, such as regulation, cell 
types other than platelets, will be more appropriate for 
such studies. To overcome this problem, McKernan et al. 
(1987) described a cell type, human erythroleukemia (HEL) 
cells, w h i c h  p o s s e s s  s u r f a c e  m a r k e r s  fo r
platelets/megakaryocytes as well as monocytes. This HEL cell 
model system derived from peripheral blood cells, grown in 
suspension, is related to human platelets. It has made it 
possible to study alpha 2 -adrenergic receptors on intact 
cells. The HEL cells system has been demonstrated to have 
alpha2 ~adrenoceptors like any other system (McKernan et al., 
1987; 1988). Using radioligand binding to study the
mechanisms of desensitization of alpha2 -adrenoceptors in HEL 
cell systems, McKernan et al. (1987) demonstrated that the 
alpha2 _adrenoceptor on this system can be detected in three 
different states:-
i) A high affinity state of the receptor which has 
been shown to represent a ternary complex 
(agonist-receptor-Gi protein) . This state is only 
identified in the cell membranes in the absence of 
guanine nucleotides which dissociate the complex 
(Bylund and U'Prichard, 1983; Limbird, 1983; 
Neubig et al., 1985).
ii) A low affinity state of the receptor for the 
agonist. This represents binding of agonist to the 
receptor only (Bylund and U'Prichard, 1983; 
Limbird, 1983; Neubig et al., 1985).
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iii) A sequestered state. This state represents 
receptors which can not be detected by epinephrine 
in an intact cell in the presence of GTP. All 
sites are however detected by UK 14,304, the 
difference between the sites detected by UK 14,304 
but not by e p i n e p h r i n e  is that they are 
sequestered. Although receptor redistribution or 
sequestration has been r e p o r t e d  for other 
receptors, this is the first for a l p h a 2  - 
adrenoceptors.
Alpha2 _adrenergic receptor translocation from the cell 
surface to the sequestered compartment has been demonstrated 
after agonist treatment, but a consistent decrease in the 
function of the receptors in inhibiting cAMP accumulation 
was not observed (McKernan et al., 1987). This observation 
gave rise to the suggestion that this system has a great 
deal of spare receptors such that receptors can be 
desensitized or removed from the cell surface without 
changes in function. Acute desensitization is not a common 
feature of alph^-adrenergic receptors (Insel and Motulsky,
1987).
Beta-adrenergic receptor kinase has also been shown to 
regulate or phosphorylate receptors that are negatively 
coupled to adenylate cyclase (Benovic et al., 1986; Mayor et 
al., 1 987; Lefkowitz and Caron, 1 989).
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1.3.2.2 M echanism of a lpha -^ -adrenoceptor 
desensitization.
Alphag-adrenoceptors have been reported to undergo
desensitization. Changes in adrenergic neuronal activity
have been reported to alter alpha^-adrenoceptor density in
brain (Reader and Briere, 1982; Vetulani et al., 1984;
Johnson et al., 1987). Rapid loss of alpha-^-adrenergic
receptor binding sites have been reported to occur within 6
hours after intrathecal infusion of phenylephrine (Astrachan
et al., 1983). Incubation of hamster vas deferens smooth
muscle with phorbol esters has been reported to cause
attenuation of alpha^-receptor mediated release of inositol
phospholipids (Leeb-Lundberg et al., 1 985), although
chronic intracerebroventricular infusion of norepinephrine
12 5had no significant effect on the density of [ I]BE 2254 
binding sites or on the magnitude of any of alpha-^- 
adrenergic receptor-mediated responses (Johnson et al.,
1987).
Recently, Leeb-Lundberg et al. (1987) have attempted to 
explain the molecular mechanisms involved in alpha-^- 
adrenoceptor desensitization as a result of agonist 
treatment. They have reported that occupation of alpha-^- 
adrenoceptor by agonists such as noradrenaline leads to 
desensitization and phosphorylation of the receptor within 
minutes of occupancy. Activation of the receptor causes 
hydrolysis of phosphatidylinositol-4-5-bisphosphate which 
leads to the generation of diacylglycerol. The liberated
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diacylglycerol a c t i v a t e s  cAMP f o r m a t i o n  w h i c h  then 
phosphorylates alphag-adrenoceptors as a process of feedback 
regulation thus leading to functional desensitization of the 
receptor. In addition to phosphorylation, agonist activation 
of the receptor causes a reduction in the accessibility of 
the receptor to ligands by promoting sequestration away from 
the plasma membrane cell surface. Hence receptor uncoupling 
appears to require only phosphorylation while receptor 
sequestration requires both phosphorylation and agonist 
occupancy. Alpha-j_-adrenergic agonists as well as other 
agonists which use diacylglycerol as a second messenger can 
undergo functional desensitization of their receptors in a 
like manner. Phorbol esters which act directly on protein 
kinase C have also been reported to cause functional 
desensitization of the alpha-^-adrenoceptor via the 
mechanisms described (Kelleher et al., 1984; Lefkowitz and 
Caron, 1987; Mayor et at., 1987; Sibley et al., 1987).
1.3.3 Hypersensitivity and Up-regulation.
The mechanism of hypersensitivity or up-regulation is 
not well understood. However, this phenomenon may be a 
consequence of blocking tonic down regulation induced by 
physiologic f l u c t u a t i o n s  in the levels of agonist 
(circulating catecholamines). Increases in receptor density 
have been observed concomitant with a fall in the levels of 
circulating catecholamines. Destruction of noradrenergic 
neurons or adrenergic antagonist treatment may lead to
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tissue hypersensitivity to catecholamines and an up- 
regulation of receptor number (Davies and Lefkowitz, 1981). 
Surgical interruption of innervation has also been reported 
to cause an increase in beta-adrenoceptor density in rat 
skeletal muscle (Banner jee et al., 1 977). Similarly, 
destruction of noradrenergic neurons by administration of 6- 
hydroxydopamine leads to an increase in both alpha- and 
beta-adrenoceptor d e n s i t y  (Hamilton and Reid, 1 9 8 2 ; 
U'Prichard et al., 1979). Increases in beta-adrenoceptor 
number as a result of these treatments has been reported to 
be accompanied by parallel increases in isoprenaline 
stimulated cAMP production (Sporn et al., 1976).
Pharmacological denervation such as treatment with 
receptor antagonists can also lead to receptor up-regulation 
(Davies and Lefkowitz, 1981). Chronic treatment with 
propranolol has been reported to cause an increased beta- 
adrenoceptor density in human lymphocytes (Aarons et al., 
1980) and doubling of beta-adrenoceptor number in rat heart 
(Glaubiger and Lefkowitz, 1977). Bylund and Martinez (1978) 
have reported increased numbers of alpha- and beta- 
adrenoceptors in rats after t r e a t m e n t  w i t h  the 
catecholamine d e p l e t i n g  agent reserpine. Chro n i c  
guanethidine has also been reported to increase beta- 
adrenoceptor density in rat hearts (Glaubiger et al., 1978). 
Treatment with alpha-adrenoceptor antagonists have also been 
reported to increase receptor number (Johnson et al., 1980; 
Vetulani et al., 1984).
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Beta-adrenergic hypersensitivity has been implicated in 
the "propranolol withdrawal syndrome" observed after 
cessation of treatment with propranolol. It has been 
attributed to the persistent up-regulation of beta- 
adrenoceptors (Alderman et al., 1974). The excessive number 
of receptors left exposed after propranolol withdrawal may 
account for the increased sensitivity observed (Davies and 
Lefkowitz, 1981). Patients with orthostatic hypotension have 
been reported to have low circulating catecholamine levels 
and increased alpha 2 _ and beta-adrenoceptor density on 
platelets and lymphocytes. Hence, administration of 
catecholamines leads to enhanced responses in these subjects 
(Hui and Connolly, 1981; Davies et al., 1981).
1.4 EFFECTS OF PATHOPHYSIOLOGICAL CONDITIONS 
ON ADRENERGIC RECEPTOR REGULATION.
1.4.1 Phaeochromocytoma.
The effects of phaeochromocytoma on alpha-adrenoceptors 
has not been well defined with some investigators finding no 
change while others observed a reduction in platelet alpha2 ~ 
adrenoceptors (Davies et al., 1981; Davies and Lefkowitz, 
1981; 1984; Snavely et al., 1982; Brodde et al., 1982;
Brodde and Bock, 1984). Lymphocyte beta-adrenoceptors have 
been reported to be down regulated in phaeochromocytoma 
(Snavely et al., 1982).
A rat model of phaeochromocytoma has been developed 
producing a distinct clinical syndrome which is due to the 
excessive production of catecholamines (40-50 fold greater
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than normal) by the tumour (Snavely et al., 1983; Tsujimoto 
et al., 1984). In this model, the beta^-adrenoceptor was 
observed to be down regulated in the heart and adipocytes 
with no significant changes in b e t ^ 2 -adrenoceptors 
(Tsujimoto et al., 1984). The down-regulation of beta-]_- 
adrenoceptors was proposed to be due to the excessive 
noradrenaline produced which has higher affinity for 
postjunctional beta^-adrenoceptors which are particularly 
sensitive to noradrenaline released from nerve endings. 
Similarly, Snavely et al. (1983) reported selective down- 
regulation of adrenergic receptor subtypes in tissues of rat 
models of phaeochromocytoma, with decreases in beta^- 
adrenoceptors in renal cortical and pulmonary membranes 
without decrease in beta 2 -adrenergic receptor number. In 
addition, a 70% decrease in the number of alpha^- but not 
alpha2 ~adrenergic receptors in membranes from renal cortex 
and lung was reported. This subtype- and tissue selective- 
down regulation of alpha-^- and beta^-adrenergic receptors 
may reflect a response to the excess noradrenaline in 
circulation as a result of this pathological condition.
1.4.2 Hype rt en s i on.
Increased sympathetic activity has been implicated in 
the pathogenesis of essential hypertension (Abboud, 1982; 
Folkow, 1982; Weber and Drayer, 1982). In animal models of 
hypertension, physiological and biochemical evidence has
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been presented for reduced beta-adrenergic responsiveness 
and parallel alterations in beta-adrenergic mediated 
adenylate cyclase activity (Feldman et al., 1984). Altered 
adrenergic responsiveness may be an important factor in the 
pathogenesis and maintenance of the hypertensive state 
(Vlachakis et al., 1977). However, in man, the physiological 
evidence of reduced beta-adrenergic responsiveness in 
hypertension is much less convincing than in animal models 
(Feldman et al., 1984). In contrast to beta-adrenoceptors, 
alpha-adrenergic hypersensitivity has been demonstrated 
(Davies and L e f k o w i t z ,  1981). S t u dies on v a s c u l a r  
adrenoceptors have provided evidence for an imbalance 
between vasoconstriction mediated by alpha-adrenoceptors 
and vasodilation mediated by beta-adrenoceptors. Decreased 
beta-adrenoceptor numbers from aorta of spontaneously 
hypertensive rats have been reported (Limas and Limas, 197 8; 
Yamada et al., 1980), while increased alpha-adrenoceptor 
number has been reported from cerebral vessels (Koybayashi 
et al., 1985). These changes however were not universal, 
since there was no change in alpha-adrenoceptor density in 
other tissues (kidney, spleen and ventricles) from the same 
model (Hick et al., 1983).
1.4.3 Heart failure.
Increased sympathetic activity has been reported as a 
compensatory response to heart failure followed by an 
increase in catecholamine levels at a later stage of the
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disease (Cohn et al., 1984). The increased catecholamine has
been reported to be predominantly noradrenaline (Thomas and
Marks, 1 978; Brodde et al., 1 98 6a). This increased 
circulation of a g o n i s t  c o u l d  lead to chan g e s  in 
responsiveness and receptor density (Fowler et al., 198 6). 
Reduced beta-adrenoceptor number in lymphocytes of patients 
with heart failure has been observed (Colucci et al., 1981).
Also Bristow et al. (1982) have demonstrated changes in
beta-adrenoceptor density in left ventricles. A decrease of 
50% in binding sites was accompanied by an almost equal 
reduction in isoprenaline-stimulated adenylate cyclase 
activity in patients with heart failure. Furthermore, a 
reduced contractile response of the failing heart to 
isoprenaline stimulation has been reported (Brodde et al., 
1986a). Brodde et al. (1986a) also reported a selective down 
regulation of beta-j_-adrenoceptor density in cardiac tissues 
of patients with congestive heart failure. Under these 
conditions, beta2 _adrenoceptors are not affected which may 
explain the beneficial effects of beta 2 -agonists in severe 
congestive heart failure.
1.4.4 Depression.
Much of what is known about the biological basis of 
depressive disorders results from an understanding of the 
biochemical pharmacology of antidepressant drugs. The 
tricyclic antidepressants and the monoamine oxidase
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inhibitors are thought to act by increasing the synaptic 
concentration of biogenic amines, while clinical depression 
can be produced by the administration of the monoamine 
depleting agent reserpine. These observations gave rise to 
the "biogenic amine hypothesis of depression". This 
hypothesis proposed that depression is caused by a 
deficiency in biogenic amine concentration at the synapses 
(Schildkraut, 1965; Charney et ad., 1981; Stahl, 1 98 4). 
However, studies have failed to discover an abnormality in 
biogenic amine metabolism in depressed patients (Charney et 
al., 1981; Sugrue, 19.83; Stahl, 1984).
The importance of an increased concentration of intra- 
synaptic biogenic amine as a necessary and sufficient 
mechanism for antidepressant effect has been questioned on 
several grounds (Sulser et al., 1979)
i) Clinically effective "atypical" antidepressants 
(mianserin, trazodone, and iprindole) fail to 
significantly inhibit MAO's or re-uptake transport 
of monoamines (Rosloff and Davies, 1974; Gluckman 
and Baum, 1969; Goodlet et al., 1977).
ii) E f f e c t i v e  a m i n e  u p t a k e  b l o c k e r s  such as
amphetamine, cocaine, femoxetine appear not to be 
useful in the treatment of depression (Overall et 
al., 1962; Post et al., 1974; Ghose et al., 1977).
iii) Inconsistencies are apparent between the time 
course of drug effects on amine availability and
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the clinical amelioration of depression. Re-uptake 
blockade and inhibition of amine catabolism occurs 
minutes after the first dose, where as clinical 
improvement takes 2-3 weeks before it manifest 
(Oswald et al., 1972; Sulser, 1979; Charney et 
al., 1981).
These observations indicated that antidepressant 
effects on amine availability can not satisfactorily account 
for their therapeutic effect. Hence, emphasis on research 
into the mechanism of action of antidepressant treatments 
has changed from acute presynaptic effects to changes in 
noradrenergic and serotonin receptors caused by chronic 
antidepressant treatment.
Changes in presynaptic receptors have been reported 
after chronic antidepressant therapy (Charney et al., 1981; 
Campbell et al., 1986) in both animals and depressed 
patients. Down-regulation of beta-adrenoceptors in parallel 
with r e d u c e d  s e n s i t i v i t y  of a d e n y l a t e  c y c l a s e  to 
isoproterenol and noradrenaline stimulation has been 
reported after chronic but not acute treatment (Banerjee et 
al., 1977; Campbell et al., 1979; Charney et al., 1981). 
Along side changes in beta-adrenoceptors, 5 -HT 2 receptors 
are also down-regulated (Peroutka and Snyder, 1980 a,b; Enna 
et al., 1981). These observations have led to a new 
hypothesis:- "Neurotransmitter r e c e p t o r  h y p o t h e s i s  of 
depression", which proposes that depressive illness is 
caused by an a b n o r m a l i t y  in the r e g u l a t i o n  of 
neurotransmitter receptors which can be corrected by
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antidepressant therapy (Charney et al., 1981; Stahl, 1984). 
Evidence that led to this hypothesis was predominantly from 
observations in normal rat brain and very little is known 
about CNS receptor changes in depressed patients or animal 
model of depression.
However, abnormalities in neuroendocrine (ACTH, TSH and 
growth hormone) secreting cells of anterior pituitary have 
been reported and are said to be reversed by drug therapy 
(Caroll et al., 1981; Heninger et al., 1984; Stahl and 
Kravitz, 1986). In addition, preliminary evidence for 
abnormalities in b e ta- and 5-HT r e c e p t o r s  exist in 
depression with the observation of night time decreased 
secretion of melatonin (beta-mediated) and prolactin (5-HT 
mediated) after tryptophan challenge (Heninger et al., 1984; 
Thompson et al., 1985).
It has been reported that platelet 5-HT reuptake and
8 . . .[H]imipramine binding sites are significantly reduced m
patients with depression (Stahl, 1983; Stahl and Kravitz,
1986) and [ H]imipramine binding sites in patients who 
commit suicide are reduced (Stanley et al., 1982). Platelet 
alpha2 _adrenoceptor binding sites are reportedly increased 
m  depressed patients when agonist sites (i.e [ H]clonidme) 
are l a b e l l e d  and not w h e n  a n t a g o n i s t  sites (e.g 
[^ H] yohimbine) are labelled ( Stahl et al., 1983; Kafka and 
Paul, 1986) but antagonist sites are said to be reduced 
after antidepressants therapy (Stahl et al., 1983; Finberg,
1987). A reduction in noradrenaline-stimulated adenylate
51
cyclase of lymphocyte beta2 ~adrenoceptors has been reported 
in depressed patient but total numbers of receptors are not 
reduced (Mann et al., 1985).
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CHAPTER TWO 
GENERAL MATERIALS AND METHODS.
New Zealand white rabbits weighing 2.00 - 3.00 kg from 
Cheshire Rabbit Farm Ltd were used for all experiments. The 
animals on arrival were housed individually in cages and 
allowed free access to food and water ad libitum. They were 
allowed to acclimatize for about three to four days before 
being used for any experiment. Except where indicated, 
groups of six or more animals were used for all the 
experiments.
2.1 Measurement of blood pressure and heart rate.
Arterial catheters were inserted into the central ear
artery of the rabbit u n der local a n a e s t h e s i a  (2% 
lignocaine) . For direct monitoring of mean arterial blood 
pressure (MAP) (mmHg), the arterial catheter was connected 
to a Grass polygraph recorder model 7B via a statham P23 ID 
transducer. The heart rate (HR) (beats/min.) was counted 
directly from the blood pressure tracing. Animals were 
allowed 30-60 minutes to rest before any readings or 
experiment was carried out on them.
2.2. Drug administration.
2.2.1 Acute infusions.
Acute drug infusions were carried out through a 
catheter which had been inserted into the marginal ear vein 
under local anaesthesia. The drug was infused via a Braun
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perfusor pump.
2.2.2 Chronic infusions.
Long term chronic drug infusions were carried out using 
osmotic minipumps (figure 2.1) model 2mll or 2002 depending 
on the duration of the drug infusion and drug solubility. 
This method of drug administration involves the implantation 
of the minipump filled with the drug which is infused via a 
catheter as described below.
2.2.2.1 Intravenous infusion.
Intravenous drug infusion was carried out via the 
femoral vein. Cannulation and implantation of the pump was 
performed under a general anaesthestic. The rabbits were 
anaesthesized with 1-2 ml of pentobarbitone sodium (60 
mg/kg) then shaved in the upper region of the thigh. The 
skin was cut open, the femoral vein located and isolated 
from the nerve and artery. The vein was then cannulated and 
the pump with the catheter firmly attached was embedded in 
the thigh muscle. After the operation the wound was stitched 
back and chloramphenicol sodium succinate (120 mg) was given 
intramuscularly and the rabbits were allowed to recover from 
the surgical procedure for an hour before being housed 
individually without restraint.
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2.2.2.2 Principle of osmotic minipump.
These devices sustain a continuous infusion of a drug 
solution when implanted subcutaneously or intramuscularly 
into the animal. The ALZETR osmotic minipump (Alza Corp., 
Palo Alto, Cal., U.S.A.) comes in various models; models 
2mll and 2ml2 hold 2.3mls of drug and infuse for one and two 
weeks, respectively while models 2001 and 2002 hold 230ul 
and infuse for one and two weeks, respectively.
The osmotic minipump consists of a water permeable 
capsule, a flexible reservoir, an osmotic material 
sandwiched between the reservoir and the capsule and a flow 
modulator. Figure 2.1 shows a diagram in which different 
components of the pump are shown.
The device acts via the following mechanism: After 
filling the reservior with a drug solution it is implanted 
subcutaneously or intramuscularly. The osmotic material 
will then absorb water from the biological environment. The 
volume of the osmotic material increases and this gradually 
compresses the central compartment (reservoir) causing a 
highly constant outflow of the drug's solution. The infusion 
rates vary from 0.5 to 50 ul/hr depending on the model.
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Figure 2.1
Diagramatic respresentation of osmotic minipump showing 
different components.
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2.2.2.3 Intracerebroventricular infusions (head
plate operations).
This method of drug administration was employed in 
infusing adrenaline and noradrenaline into the cerebral 
ventricle of rabbits since these drugs do not cross the 
blood brain barrier when administered peripherally.
For insertion of a cannula into the cerebral ventricle, 
a head plate was used as a guide to hold the indwelling 
cannula in position. After the rabbit had been anaesthesized 
and the head shaved, the skull was exposed by cutting the 
skin. The skull was then cleared of connective tissue to 
make the sutures on the skull visible (figure 2.2). The 
reference point for mounting the head plate is the meeting 
point of coronal and sagital sutures (bregma) on which the 
reference point on the head plate (figure 2.3) was mounted. 
With the reference point of the head plate on the bregma, 
the plate was held in place by stainless steel self-tapping 
screws after a hole had been drilled on the skull with a 
hand drill. When the head plate was in position, 1.5 mm 
behind the bregma (coronal suture) and 2 mm lateral, a hole 
was bored for the insertion of the cannula. The cannula was 
15 mm long to enable it to be well within the cerebral 
ventricle when inserted (figure 2.3). (Figure 2.4 shows 
cerebral ventricle from different brain sections). The 
cannula was then screwed on to the head plate. P.E 10 tubing 
attached to an osmotic minipump (model 2002) which had been 
filled with the drug was then connected to the exposed end
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Head plate Cannula
Figure 2.3
Diagramatic representation of head plate and cannula.
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Figure 2.4
Sections of rabbit brain showing position of ventricles.
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of the cannula and the minipump was embedded in the shoulder 
muscle. At the end of the operation the rabbit was given 12 0 
mg of chloramphenicol sodium succinate intramuscularly and 
allowed to recover from the anaesthesia before being 
returned to its cage.
In pilot studies dye was injected to check that the 
position of injection and of the cannula was right. The 
method was mastered before being used for the study.
2.3 Intracisternal injection.
For intracisternal injection animals were anaesthetized 
lightly using pentobarbitone sodium and shaved over the 
occiput and back of the neck. Clonidine was injected into 
the cisterna magna as appropriate by a free hand 
transcutaneous injection in a total volume of 100 ul 
(Chalmers and Wurtman, 1971) and blood pressure and heart 
rate monitored as described in each section.
2.4 Radioligand binding assays.
2.4.1 Tissue preparations.
At the end of the experiments, rabbits were killed with 
an overdose of intravenously injected pentobarbitone sodium. 
The brain and kidney were removed, placed on ice and 
cleansed of excess blood. The brain was dissected into 
forebrain and hindbrain, at the level of colliculi. The
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tissues were chopped finely in ice cold 0.32 M sucrose (40 
ml), then homogenised using a Brinkman Polytron at a setting 
of 5 and centrifuged for 15 minutes at 1500 rpm. The 
supernatant was collected discarding the pellet consisting 
of fibrous tissues, red cells and other high density debris. 
The supernatant was recentrifuged twice at 30,000 rpm for 15 
minutes at 4°C. The resulting membranes were washed in ice 
cold Tris HC1 buffer 50 mM pH 7.5 and recentrifuged under 
the same conditions. The pellet was finally resuspended in 
50 mM Tris HC1 buffer and assayed at a wet weight 
concentration of 20-25 mg/ml or stored at -70°C until 
required for assay.
2.4.2 Alpha0- and Beta-adrenocetor binding assays.
Receptor binding studies were carried out on a final
volume of 1 ml consisting 0.8ml of tissue homogenate, 0.1ml
— 5radioligand and 0.1ml of buffer or p h e n tolamme 10 M for
_ 7
alpha2 ~adrenoceptor assays or propranolol 4 x 10 M for 
beta-adrenoceptor assays. The tubes in duplicate were 
incubated at 25°C for 25 minutes in a shaking water bath. 
Incubation was terminated by rapid vacuum filtration through 
glass fibre filters (Whatman GF/B): The filters were rinsed 
twice with 5 ml of Tris HC1 buffer, placed in glass vials 
and left to dry overnight. The vials plus filters were then 
filled with 10 ml of Optiphase Triton X scintilation liquid. 
The radioactivity was counted in a Packard Tri-cab model 
3255 liquid scintillation counter at an efficiency of 36%.
The following ligands were used:- [^ H]yohimbine (1.25-37.5 
nM), [^H]idazoxan (0.5-20.0 nM or [^ H]dihydroalprenolol 
(0.15-7.2 nM).
2.4.3 Data analysis.
Specific binding was defined as the difference in 
radioactivity bound between samples containing buffer and 
those containing displacing agent. The maximum number of 
binding sites (Bmax) and dissociation constant (KD) were 
obtained from modified Scatchard plot (1949) analysis of 
free/bound vs free this being preferred to the more usual 
bound/free vs bound plot. Bmax was then corrected for 
protein which was assayed by the method of Lowry et al. 
(1951) and expressed as fmoles/mg protein.
2.5 Statistical analysis.
The data generated in this thesis from radioligand 
binding assays were subjected to unpaired t-test analysis. 
Other analyses carried out are as indicated in the 
appropriate section.
2.6 Tissue catecholamines.
Sucrose homogenates of tissues were prepared by 
homogenising tissues in 40 ml of 0.32 M sucrose. This
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sucrose homogenate was taken and an equal volume of 0.2% 
perchloric acid added. The mixture centrifuged at 2,000 rpm 
for 15 minutes at 4°C. The supernatant was harvested into 
tubes and stored at -70°C until assayed using high 
performance liquid chromatography with electrochemical 
detection (HPLC-ECD) (Hashimoto and Maruyama, 1977; Howes et 
al., 1983).
2.7 Materials.
New Zealand white rabbits were obtained from Cheshire 
Rabbits Farm, Tarpoley, Cheshire. [JH ] Yo h i m b i n e ,
O Q
[JH]idazoxan and [ H] dihydroalprenolol were supplied by 
Amersham International U.K. Clonidine HC1, (-)adrenaline 
bitartarate, (-)noradrenaline HC1, phentolamine mersylate, 
yohimbine HC1, rauwolscine HC1, propranolol, oxymetazoline, 
haloperidol, metanephrine and normetanephrine were bought 
from Sigma U.K. Metoprolol and ICI 118551 were obtained from 
ICI U.K and amitriptyline HC1 from M.S.D U.K. Idazoxan 
(Reckitt and Coleman, Kent), guanabenz (Wyeth, U.K.) and 
prazosin (Pfizer, U.K.) were gifts. Alzet osmotic minipumps 
were obtained from Scientific Marketing, London.
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CHAPTER THREE
CHARACTERISTICS OF [ 3H] YOHIMBINE AND [3H] IDAZOXAN
BINDING SITES.
3.1.1 INTRODUCTION.
Alpha2 -adrenoceptor ligands have proved to be valuable 
tools in elucidating receptor mechanisms and classification.
Early ligands used in classifying alpha 2 ~adrenoceptors
3 . 3  included [ H] a d r e n a l i n e ,  [ H] n o r a d r e n a l i n e  and
o
[ JH] dihydroergocryptine (U'Prichard and Snyder, 1 97 7;
Greenberg and Snyder, 1977), but these ligands could not
distinguish between alpha-j_- and alpha 2 -receptors and even
sometimes labelled other adrenergic receptors (Lefkowitz and
Williams, 1977; Tittler et al., 1977). The agonist ligands 
3 3[ H] clomdine and its analogue [ H] p a r a - a m i n o c l o n i d m e
3together with the antagonist ligands [ H]yohimbine and
3 . . .[ H] rauwolscine were the first selective alpha 2 -ligands
developed (Perry and U'Prichard, 1981; Nomura et al., 1984).
Anomalies in binding characteristics between the two ligands
soon became apparent. These differences were initially
thought to be due to agonists binding preferentially to the
high affinity state of the receptor while the antagonist
ligands bind both high and low affinity states equally
(Hoffman and Lefkowitz, 1 980). This however would not
explain all the differences observed and based on a
3 . 3compansion of [ H] clomdine and [ H] yohimbine binding in a
series of tissues, the possibility of alpha 2 -adrenoceptor
subtypes was suggested (Bylund, 1981). Differences in the
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3 . 3displacement of [JH]rauwolscine and [ H]yohimbine from their
binding sites have been observed (Cheung et al., 1982;
Neylon and Summers, 1985; Alabaster et al., 1986). These
observations also led the proposal of heterogeneity of the
alpha2 ~receptor. These ligands appear to bind to two
distinct sites which are most readily distinguished by their
affinities for prazosin and o x ym et a zo 1i ne . Variations
between the relative densities of the binding sites of the
ligands have also been observed between species and tissues
(Bylund, 1985; Dickinson et al., 1986).
Recently, a n o t h er  a l p h a 2 - a d r e n o c e p t o r  l igand
[ H] idazoxan has b e c o m e  available. I d az o xa n  is an
imidazoline derivative and has been shown to be a selective
and potent alpha2 ~adrenoceptor antagonist (Dettmar et al.,
1983; Hannah et al., 1 983; Convents et al., 1 98 7).
•3
[JH] Idazoxan has also been shown to bind to alpha 2 _
adrenoceptor sites in rat tissues (Doxey et al., 1983).
However, Boyajian et al. (1987) have recently presented
autoradiographic and pharmacological evidence suggesting
that [ H]idazoxan labels two distinct alpha 2 ~adrenoceptor
populations in rat brain with high affinity, only one of
3which is labelled by [ H]rauwolscine. To confuse the picture
3 3further, [ H] c l o m d i n e  and its a n al o gu e  [ JH] para-
aminoclonidine have been reported to bind to non-adrenergic
sites in addition to binding at adrenergic sites (Ernsberger
et al., 1987). Recently, evidence has been presented showing
that idazoxan may also label sites distinct from the alpha2 ~
adrenoceptor site. These sites have been referred to as
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imidazoline or idazoxan binding sites (Hamilton et al., 
1988; Lachaud et al., 1988; Wikberg, 1988; Yablonsky et al., 
1988; Vigne et al., 1989).
This chapter (3), examines the characteristics of 
[ JH] yohimbine and [JH] idazoxan binding sites using various 
adrenergic drugs to displace them from their binding to 
forebrain and kidney membranes from rabbit and rat brain 
tissues.
3.1.2 METHODS.
Rabbit forebrain and kidney membranes were prepared as 
described in methods 2.4 (n = 6 ). Rat forebrain membranes 
were prepared in a similar manner. Saturation binding assays 
were carried out on the tissue homogenates as described in 
methods section 2.5. In addition, the inhibition of specific
r> o
binding of [ H] yohimbine (6.25 nM) and [ H] idazoxan (2.5 nM) 
were studied in the presence and absence of increasing 
concentrations of a range of alpha-adrenergic agonists and 
antagonists. The tissue homogenates plus the ligand and 
competing drug in a total volume of 1 ml were incubated as 
described in section 2.5 of the .methods. The monoamine 
oxidase inhibitor pargyline (10 nM) was added to assays 
containing adrenaline and noradrenaline along with ascorbate 
to prevent oxidation. Agonist displacement assays were 
incubated at 0°C for 16 hours to maintain the receptors in 
the high affinity state. The inhibition curves were plotted
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and the concentration of displacing agent capable of 
reducing the specific binding of the ligands by 50% (IC^q) 
was obtained from the inhibition curves and used as a 
measure of the relative affinity of the displacing agents 
for the binding site. The displacing agents examined were as 
follows adrenaline, noradrenaline, clonidine, guanabenz, 
oxymetazoline, yohimbine, rauwolscine, idazoxan, prazosin, 
phentolamine, haloperidol, methysergide and propranolol.
3.1.3 RESULTS.
3 .1.3 .1 Saturation binding experiments.
Significant differences were observed in the number of 
binding sites of both ligands in both forebrain and kidney 
membranes. [^ H] Yohimbine labelled 126 + 55 fmoles/mg
protein in the forebrain which was significantly different
•3
(p < 0.05) from the number of sites labelled by [ H]idazoxan 
58 + 19 fmoles/mg protein. In the kidney, [ H ]idazoxan
labelled 209 + 64 fmoles/mg protein which was significantly 
(p < 0 .0 1 ) greater than the number of sites labelled by 
[^H] yohimbine 7 0 _+ 8 fmoles/mg protein. There was no 
significant difference between the affinities of the ligands 
in either tissue studied (Table 3.1).
3 .1.3.2 Inhibition experiments.
The ability of various adrenergic drugs to displace the 
specific binding of [^H]yohimbine (6.25 nM) and [^H]idazoxan 
(2.5 nM) from rabbit brain and kidney membranes and rat
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brain tissues were examined. The potency of alpha 2 ~
•3
adrenoceptor agonists in displacing [JH]yohimbine and 
[^H] idazoxan from their binding to rabbit brain membranes 
are illustrated in figures 3.1 and 3.2, respectively. At the
*3 . . .
[ H ] yohimbine binding site, the order of potency of
oxymetazoline > guanabenz > clonidine was observed while at
-3
the [JH]idazaxan binding site the order was completely 
different, being guanabenz »  clonidine > oxymetazoline. In 
addition, the endogenous adrenoceptor agonists adrenaline
*3
and noradrenaline were unable to displace [JH]idazoxan from 
its binding site in the rabbit brain but displaced
[ H]yohimbine with an equal potency with IC^q of 450 nM
■3
(Table 3.2). However, [H]idazoxan binding to the rat 
forebrain was displaced by adrenaline and noradrenaline with 
an IC^q of 180 and 400 nM, respectively (Table 3.2).
In the antagonist inhibition experiments, the order of 
potency of yohimbine > rauwolscine > idazoxan > phentolamine
•3 , ,
>> prazosin was observed at [ H]yohimbine binding sites
*3 . . .
(figure 3.3) while at [ H]idazoxan binding sites the order 
of potency observed was idazoxan > phentolamine > yohimbine 
= rauwolscine > prazosin (figure 3.4). The IC^o's for 
propranolol, methysergide, haloperidol at both ligands 
binding sites were high, in the micromolar (urn) region. In
•3
the kidney, the displacement of [JH]idazoxan by adrenergic 
drugs is consistent with the order obtained in the forebrain 
and the same is true for inhibition of [^H] yohimbine. The 
IC^q values are summarised in Table 3.2.
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Since the Hill coefficient was significantly less than 
1 in some cases for agonist displacement, relative drug 
potencies are expressed as IC50 instead of Ki. For 
individual points on the curves the standard deviation 
varied between 5 - 20%, mean values only shown on the 
figures for clearity.
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TABLE 3.1
[■^ H] Yohimbine and [^H]idazoxan binding sites (Bmax) in the 
rabbit forebrain and kidney membranes.
Forebrain 
Bmax Kd 
(fmoles/mg protein) (nM)
Kidney
Bmax
(fmoles/mg protein)
k d
(nM)
Ligands:-
[^H]Yohimbine 126 + 5 5  9 + 3 58 + 19 9 + 4
[^H]Idazoxan 7 0 + 6 *  4 + 2 209 + 64** 6 + 2
Result:- mean +• S.D * P < 0.05, ** P < 0.01, using unpaired t-test.
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Figure 3.1
o
Displacement of specific [ H] yohimbine binding from rabbit 
brain membranes by alpl^-adrenoceptor agonists: Q guanabenz, 
A  oxymetazoline, • clonidine. n = 4 - 6 .
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Displacement of specific [JH]idazoxan binding from rabbit 
brain membranes by alpha2-adrenoceptor agonists: O  guanabenz, 
• clonidine, A  oxymetazoline, n = 4 - 6 .
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TABLE 3.2
RELATIVE AFFINITIES OF ALPHA2-ADRENOCEPTOR DRUGS ON [ 3 H]YOHIMBINE 
AND [3 H]IDAZOXAN BINDING SITES. (IC5 0  nM)
n = 4 - 6 [3 H]Yohimbine i3 H]Idazoxan
Rabbit 
FB kidney Rat FB
Rabbit 
FB kidney Rat FB
Alpha2 _agonists
Adrenaline 356 278 1 2 0 0 >5000 >5000 180
Noradrenaline 341 208 1600 >5000 >5000 400
Guanabenz 1999 - - 2 . 8 - 4.5
Oxymetazoline 600 - - >5000 >5000 -
Clonidine >5000 - - 800 - 40
Metanephrine >5000 - - >5000 - -
Normetanephrine >5000 - - >5000 - -
Alpha2 -ant agoni st s
Phentolamine 107 180 40 487 544 30
Yohimbine 2 2 2 2 24 >5000 >5000 90
Rauwolscine 1 0 7 - >5000 >5000 1 0 0
Idazoxan 127 76 50 1.7 1 . 8 1 . 2
Others
Prazosin >5000 >5000 >5000 >5000 >5000 2 0 0 0
Propranolol >5000 >5000 >5000 >5000 >5000 >5000
Methysergide >5000 >5000 - >5000 >5000 >5000
Haloperidol >50 00 >5 00 0 - >5000 >5000 -
FB = forebrain
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Figure 3.3 
3Displacement of specific [ H]yohimbine binding from rabbit 
brain m e m b r a n e s  by alpha-adrenoceptor antagonists:
A  yohimbine, A rauwolscine, •  idazoxan, O  phent o 1 am ine, 
□  prazosin, n = 4 - 6 .
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*3
Displacement of specific [ H] idazoxan binding from rabbit 
brain membrane s by alpha-adrenoceptor antagonists: 
•  idazoxan, O  phentolamine, □  prazosin, A yohimbine, 
A rauwolscine, n = 4 - 6 .
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Compounds with imidazol(in)e or closely related structures
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3.1.4 DISCUSSION.
The data p r e s e n t e d  in d i c a t e  that the ligands 
3 3[ H]yohimbine and [ H]idazoxan bind to receptor populations
which are significantly different in both rabbit forebrain
and kidney membranes. The number of binding sites for the
two ligands differed significantly. In addition, the
inhibition experiments indicated the difference between the
binding properties of these ligands in the rabbit, while
differences between rat and rabbit provide further evidence
for adrenoceptor heterogeneity between rodents and other
species. The high IC^q (uM) obtained for non alpha 2 _
adrenergic drugs namely propranolol, prazosin, methysergide
and haloperidol suggest that the differences observed
between the two ligands were not as a result of either
ligand binding to beta-, alpha-^-, serotonin or dopamine
3sites. The IC^q values obtained with [ H]yohimbine were 
similar to those reported in rabbit tissues by others and 
are consistent with binding at alpha 2 -adrenoceptor sites 
(Cheung et al., 1982, Bylund, 1985, Neylon and Summers, 
1985, Dickinson et al., 1986). [JH]Idazoxan binding has not 
been extensively studied in rabbit membranes, but the IC^q 
values obtained in rat forebrain were consistent with those 
reported by others (Doxey et al., 1983; 1984) and consistent 
with the ligand binding to an alpha2 -adrenoceptor. However, 
the high values of IC^q obtained for displacement of 
[^ H] idazoxan by catecholamines and several of the alpha 2 - 
adrenoceptor antagonists in the rabbit membranes are hard to 
reconcile with the ligand binding to alpha 2 -adrenoceptors.
Idazoxan has been shown to be a potent and selective alpha 2 ~ 
adrenoceptor antagonist in vivo in the rabbit and rat 
(Dettmar et al., 1983; Doxey et al., 1983; Hannah et al., 
1983) . It is possible that the failure to observe specific 
binding to alpha 2 ~adrenceptors with [^H]idazoxan in the 
rabbit membranes was related to the procedures used 
resulting in degradation of either the ligand or the alpha2 ~ 
adrenoceptor binding site. However, this is unlikely since 
using identical methodology, the binding of [^H]idazoxan to
r>
rat membranes and [ H]yohimbine to rabbit membranes was 
entirely consistent with binding to alph^-adrenoceptors.
The compounds most potent at displacing [H]idazoxan 
binding all had imidazoline or closely related structures 
(figure 3.5). An imidazoline binding site has been proposed 
and compounds with imidazoline/imidazole structures have been 
shown to bind at this site (Coupry et al., 1987; Ernsberger 
et al., 1987; Bricca et al., 1988; Wikberg, 1988; Yablonsky 
et al., 1988; Vigne et al., 1989). It has also been reported 
that imidazoline/imidazole drugs including clonidine, ST 589, 
cirazoline produce dose-dependent hypotension when micro­
injected into the rostral ventrolateral medulla and nucleus 
reticularis of rat (Meeley et al., 1986; Bousquest et al., 
1984; Tibirica et al., 1988). In contrast, injection of 
catecholamines such as alpha-methylnoradrenaline and 
noradrenaline which have high selectivity for alpha 2 ~ 
receptors did not have any effect on blood pressure 
(Bousquet et al., 1984). These hypotensive effects have
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been shown to be independent of a mechanism involving alpha- 
adrenoceptors (Meeley et al., 1986). These observations are 
similar to the report that on the peripheral alpha- 
adrenoceptors structural requirements of catecholamine 
sensitive sites are different from those of imidazoline 
sensitive sites in smooth muscle (Ruffolo et al., 1977; 
1982; Ruffolo and Waddell, 1982). In addition, a low 
molecular weight substance has been isolated from bovine 
brain w h i c h  has been s h o w n  to p o t e n t l y  d i s p l a c e
3 o[H]clonidine and [ H]para-aminoclonidine binding to alpha2 ~ 
adrenoceptors in rat brain (Atlas and Burstein., 1984; 
Diamant and Atlas, 1986; Meeley et al., 1986). This 
substance has been named clonidine displacing substance and 
has been reported to be biologically active (Meeley et al., 
1986; Bousquet et al., 1986; Felsen et al., 1987). It has 
been proposed that this substance may be producing its 
effect via the imidazoline binding site (Meeley et al., 
1986). It is also possible that this site can be equated 
with the idazoxan binding site. However, one potential 
problem that might arise as a result of using antagonists 
ligands is that they may not identify the exact site at 
which the endogenous neurotransmitter acts, agonists tend to 
be small molecules with hydrophobic centre (Ariens and 
Simonis, 1983), while the characteristics of antagonists 
tend to favour binding to lipophilic sites which are close 
to the polar sites acted upon by agonists. Idazoxan could 
bind to an allosteric site at or adjacent to the alpha 2 ~ 
adrenoceptor. In support of the latter hypothesis, parallels
82
may be drawn with the the methysergide / 5-HT binding site. 
Methysergide readily displaces [ 3H]ketanserin from brain 
membranes but it only displaces a small portion of 
specifically bound ketanserin from platelets of several 
species. It has been suggested that this may be due to 
methysergide binding to an allosteric site which is distinct 
from the 5 -HT2 receptor (Fenken and Kaumann, 1987). However, 
such explanations are tentative and further investigations 
including functional studies need to be undertaken to 
explain the characteristics of [^H]idazoxan binding to 
rabbit tissue membranes observed in this study.
3.2 SPECIFICITY OF [3 H]DIHYDROALPRENOLOL AS A 
BETA-ADRENOCEPTOR LIGAND.
3.2.1 INTRODUCTION.
Early ligands employed in the characterization of beta- 
adrenoceptors included [ H] adrenaline, [ H] alprenolol and 
[3H]dihydroalprenolol (U'Prichard and Snyder, 1977; Greenberg 
and Snyder, 1977). These ligands were found to have low 
specific activity. The development of high specific activity 
ligands s u c h  as [ x J I ] l o d o c y a n o p i n d o l o l  a n d  
[125ij dihydrobenzylpindolol followed, however both ligands 
have been shown to bind to other receptor sites in the brain, 
serotonin and dopamine for example (Engel et al., 1981; 
Hoffman and Lefkowitz, 1980). Thus despite the low specific 
activity of [3H]DHA, it has the advantages of not binding to
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other receptor sites and has been increasingly employed in 
characterizing beta-adrenoceptors in various tissues and 
species (Bylund and Snyder, 1976; Davies and Lefkowitz, 1981; 
Stone and U'Prichard, 1981; Chang and Lotti, 1983).
This section is intended to substantiate the binding 
characteristics of [^ H]DHA by displacement from its binding 
sites in the rabbit brain by the beta-adrenoceptor 
antagonists propranolol, ICI 118551 and metoprolol.
3.2.2 METHODS.
Rabbit tissue homogenates were prepared as described in 
methods (2.4.1) (n = 4). The non selective beta-adrenoceptor 
ligand [JH]dihydroalprenolol ([JH]DHA) was used to measure 
the specificity of its binding to rabbit brain homogenates 
in the presence or absence of increasing concentrations of 
beta-adrenoceptor drugs. Propranolol, ICI 118551 and 
metoprolol were incubated with [ H] DHA and tissue 
homogenate as described in section 2.4.2 of the methods. 
Displacement curves were plotted as percentage inhibition 
against the negative logarithum of the drug concentration. 
The concentration of drugs required to displace 50% (IC5 q) 
of the specifically bound radioactivity was calculated from 
the displacement curves and used as measure of drug 
affinity..
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3.2.3 RESULTS.
The displacement of specific [^H]DHA binding rabbit 
brain tissue homogenates was studied and the IC^q (nM) 
obtained from displacement curves. The order of potency at
o
displacing [°H]DHA from it binding site was propranolol (70 
nM) > ICI 118551 (80 nM) > metoprolol (200 nM) . However, the 
Hill slopes for metoprolol and ICI 118551 were shallow. A 
summary of the results is presented in table 3.3.
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Table 3.3
Relative potencies of beta-adrenoceptor antagonists on 
[JH]dihydroalprenolol
Drugs IC5 0 (nM)
propranolol 70 -
ICI 118551 80
metoprolol 2 0 0
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3.2.4 DISCUSSION.
The beta-adrenergic receptor antagonist [^H]DHA has 
been widely used to label total receptor numbers in 
membranes from various organs and species (Bylund and 
Snyder, 1976; Stone and U'Prichard, 1981; Brodde et al.,
1981) . The site labelled by this ligand has been shown to 
have characteristics which are very similar to the beta- 
adrenoceptor (Lefkowitz, 1978). Correlations have also been 
observed in the ability of various beta-adrenoceptor drugs
•5 ,
to compete for [ H]DHA binding sites and the ability of the 
same agents to stimulate or antagonise beta-adrenoceptor 
coupled adenylate cyclase (Murkerjee et al., 1976). This 
observation is consistent with the [ H]DHA binding site 
representing the physiological beta-adrenergic receptors.
In these experiments, it has been observed that 
specific [^ H]DHA binding was inhibited with high potencies 
by propranolol a non-selective beta-adrenoceptor antagonist 
and ICI 118551 a beta2 ~selective antagonist and metoprolol a 
beta-j_-selective antagonist. Displacement curves for 
metoprolol and ICI 118551 were shallow with Hill slopes less 
than one. This would be consistent with the presence of both 
beta-j_- and beta 2 -adrenoceptors in the rabbit brain. The 
relatively low potency exhibited by metoprolol could be due 
to the fact that both beta-|_- and beta 2 -receptors exist in 
the brain with beta 2 ~receptor being present in greater 
numbers than beta]_-adrenoceptors. The results obtained in 
these experiments are consistent with previous studies 
(Lefkowitz, 1 978; Brodde et al., 1981). Thus, results
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indicate that [ H]DHA labels beta-adrenoceptor m  the rabbit 
brain in these studies.
88
CHAPTER FOUR
EFFECTS OF CHRONIC IDAZOXAN AND YOHIMBINE TREATMENTS ON
ADRENOCEPTORS IN THE RABBIT.
89
CHAPTER FOUR
EFFECTS OF CHRONIC IDAZOXAN AND YOHIMBINE TREATMENTS ON
ADRENOCEPTORS IN THE RABBIT.
4.1 INTRODUCTION.
Previous studies on central and peripheral adrenergic 
receptors have shown that long term receptor stimulation in 
vivo or chronic agonist administration desensitizes (down- 
regulates) receptors (Hoffman and Lefkowitz, 1980; Davies 
and Lefkowitz, 1981), while noradrenergic nerve depletion or 
chronic receptor blockade supersensitizes (up-regulates) 
both alpha- and beta-adrenoceptors (U'Prichard and Snyder,
1978; U'Prichard et al., 1979; Lefkowitz et al., 1983; 
Nahorski and Barnett, 1982).
Up-regulation of alpha 2 _adrenoceptor number has been 
reported to occur in rat brain after treatment with the 
alpha2 ~adrenoceptor antagonist yohimbine (Johnson et al.,
1980), while treatment with reserpine a catecholamine store 
depleting agent has been reported to cause an increase in 
[^H]catecholamine binding sites in the rat brain (U'Prichard 
and Snyder, 1978). Bylund and Martinez (1980) also reported 
an increase in rat salivary gland alpha2 ~adrenoceptor number 
after reserpine treatment. In addition, surgical and 
pharmacological denervation by administration of 6 - 
hydroxydopamine have been said to cause up-regulation of 
both alpha- and beta-adrenoceptor density in the brain 
(U'Prichard et al., 1979; Sporn et al., 1979). Increases in 
beta-adrenoceptors in rat heart and skeletal m u s c l e  
following guanethidine treatment and denervation have been
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demonstrated (Banerjee et al., 1977; Glaubiger et al., 
1978) . Chronic administration of propranolol to healthy 
volunteers has been reported to lead to a significant 
increase in beta 2 ~adrenoceptor density in circulating 
lymphocytes (Aarons et al., 1 98 0; Aarons and Molinoff,
1982). Such an enhanced adrenoceptor density after chronic 
antagonist treatment has been implicated in tachyphylaxis 
and withdrawal phenomena and could also account for side 
effects observed after some treatments, enhanced beta- 
adrenoceptor density after chronic propranolol treatment has 
been proposed to be responsible for "propranolol withdrawal 
syndrome" (Alderman et al., 1974; Davies and Lefkowitz,
1981). However, increases in receptor density after 
antagonist treatment are not an ubiquitous finding. 
Administration of beta-adrenoceptor antagonists with partial 
agonist activity like pindolol have been reported to cause a 
significant decrease in lymphocyte be t a 2 ~adrenoceptor 
density (Aarons and Molinoff, 1982; Giudicelli et al., 1976; 
Brodde et al., 1986b). Neve and Molinoff (1986) also 
reported decrease in beta-adrenoceptor density after 
treatment with celiprolol and pindolol beta-adrenoceptor 
antagonists with intrinsic sympathomimetic activities.
Yohimbine and idazoxan have been shown to be potent and 
selective alpha 2 -adrenoceptor antagonists (Perry and 
U'Prichard, 1981; Doxey et al., 1983; Hannah et al., 1983; 
Convents et al., 1987; Ruffolo et al., 1988). However, 
recently idazoxan has been reported to bind principally to a
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non-adrenergic site in addition to binding to alpha 2 ~ 
adrenergic receptors (Coupry et al, 1987; Lachaud et al., 
1988; Yablonsky et al, 1988; Wikberg 1988; Vigne et al., 
1989; chapter 3) .
This chapter [4], is therefore intended to compare
effects of chronic yohimbine and idazoxan treatment on 
3 3[ H] yohimbine and [ H] idazoxan binding sites in tissue 
membranes from rabbits. In addition effects on alpha 2 _ 
adrenoceptor mediated pressor reponses to bolus doses of 
alpha-methylnoradrenaline injection in concious rabbits and 
the depressor response induced by intracisternal injection 
of clonidine to anaesthesied rabbits were examined.
4.2 METHODS.
The experiments were performed using male New Zealand 
white rabbits (2.5-3.0 kg) from Cheshire Rabbit Farms. The 
animals were housed individually and allowed access to food 
and water ad libitum
4.2.1 In vivo drug infusion.
Groups of rabbits (n = 8 - 12) received either acute 
(30 minutes) or chronic (5 days) idazoxan infusions, while 
yohimbine was administered intraperitoneally for 5 days. 
Since idazoxan was a relatively new drug and few chronic 
studies have been carried out using this animal model, it 
was necessary to carry out a series of preliminary studies
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with short term infusions to select the appropriate 
effective dose for chronic study. In contrast, the dose used 
for the yohimbine study was selected from previous 
publications (Johnson et al., 1980; Scott and Crews, 1983). 
Yohimbine had to be given intraperitoneally as solubility 
problems limited its administration via osmotic minipump. 
Control groups received 0.9% saline.
4.2.1.1 Idazoxan infusions.
Idazoxan dissolved in 0.1% ascorbate was acutely 
infused via a marginal ear vein cathether inserted under 
local anaesthesia (2% lignocane) . The infusion was carried 
out (for 30 minutes) at the rate of 0.56 or 1.1 mg/hr using 
a Braun perfusor pump.
Chronic (5 days) infusions were carried out using 
AlzetR osmotic minipumps (model 2mll) (figure 2.1), 
implanted as described in section 2.2.2. The concentration 
of idazoxan in the pump was adjusted so that the infusion 
rate (1 . 1  mg/kg) was the same as in the acute experiments. 
Control groups were implanted with pumps delivering vehicle 
ascorbate.
4.2.1.2 Yohimbine treatment.
Because of problems with solubility, yohimbine 15 
mg/kg/day in d i v i d e d  d o s e s  w a s  a d m i n i s t e r e d  
intraperitoneally for 5 days and was not given continuously
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via osmotic minipumps. Control groups received vehicle 
ascorbate by a similar route.
4.2.2 Pressor dose-response curves to alpha- 
methylnoradrenaline.
Dose-reponse curves to alpha-methylnoradrenaline (5 - 
1 0 0  ug) were constructed in groups of rabbits before and 
after pretreatment with yohimbine or idazoxan. Intravenous 
and arterial lines were inserted for infusion of drugs and 
measurement of blood pressure as described in section 2 . 1  
and 2 .2 .1 . 2  of methods.
4.2.3. Intracisternal injections of clonidine.
To observe effects of treatment on depressor responses 
to c l o n i d i n e ,  c l o n i d i n e  1 u g / k g  was i n j e c t e d  
intracisternally to groups of rabbits treated chronically 
with saline, idazoxan or yohimbine. Clonidine was 
administered by a free hand transcutaneous injection 
(Chalmers and Wurtman, 1971) in a total volume of 100 ul 
while the rabbits were under light anaesthesia (sodium 
pentobarbitone 30-60 mg/kg) . Changes in mean arterial 
pressure (MAP) and heart rate (HR) were monitored before and 
continuously for 5 minutes after the injection then at 15 
minutes interval thereafter until 60 minutes after the 
injection.
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4.2.4 Tissue preparation.
At the end of the experiment rabbits were killed with 
an overdose of sodium pentobarbitone (I.V). The brain and 
kidney removed, placed on ice and cleansed of connective 
tissue and blood. The brain was dissected at the point of 
colliculi into fore and hindbrain. The tissues were prepared 
as described in section 2.4.1 of the methods.
4.2.5. Radioligand binding assays.
Receptor binding studies were performed on tissue 
homogenates using [JH]idazoxan (0.5-20 nm) for labeling
*3
idazoxan / imidazoline binding sites and [H]yohimbine
■3
(1.25-37.5 nm) for alpha 2 ~adrenoceptors and [ H ]DHA for 
beta-adrenoceptors and incubated as described in section 
2.4.2. The radioactivity was counted using a Packard Tri-Cab 
Model 3255 liquid scintillation counter at an efficiency of 
36%.
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4.2.6. Data analysis.
To analyse the alpha-methylnoradrenaline dose response 
curves, curves were constructed for each individual and the 
dose required to increase MAP by 50 mmHg for yohimbine 
treated groups and 30 mmHg for idazoxan treated groups and 
their respective controls were obtained from the dose- 
response curves. The difference between the treated and 
control groups were analysed by unpaired t-test. In addition 
the shift in the dose response curves in the treated groups 
relative to the controls were calculated as dose ratios. The 
binding parameters Bmax and KD were obtained from the 
modified Scatchard analysis. Statistical analysis of the 
differences between groups of data generated by Scatchard 
plots were analysed using unpaired t-test. Data from the 
depressor response induced by intracisternal injection of 
clonidine were analysed by analysis of covariance using the 
package Rummage (Bryce, 1980) run on an ICL 2988 mainframe 
computer. The preinjection blood pressure was used as the 
covariate. All results are expressed as mean + S.D.
4.3 RESULTS.
4.3.1 Blood pressure and heart rate.
There was no significant change in the resting blood 
pressor or heart rate of the rabbits during either idazoxan 
or yohimbine treatment, neither were there any obvious 
behavioural changes during the course of the experiments.
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4.3.2 Effects of antagonist treatments on pressor 
responses to alpha-methylnoradrenaline.
In preliminary experiments, idazoxan infusion for 30 
minutes attenuated the response to bolus doses of alpha- 
methlynoradrenaline, the dose required to raise the MAP by 
30 mmHg was increased from 17.4 + 3.2 for control to 22.4 _+ 
4 ug for 0.56 mg/kg/hr infused and the curve was shifted to 
the right with a dose ratio of 1.3, while for 1 . 1  mg/kg/hr 
infusion, the dose was increased from 17.4 + 2 for control 
to 27.5 +_ 5 ug for treated and the curve was shifted to the 
right with a dose ratio of 1.6 (figure 4.1). On the basis 
of these results the higher dose was selected for detailed 
chronic study. In the chronic study with 1.1 mg/kg/hr, the 
dose required to increase the MAP by 30 mmHg was increased 
from 19.1 +_ 5 for control to 35.5 _+ 4.3 ug for treated group 
and the curve was shifted to the right with a dose ratio of
2.0 (figure 4.2) .
Treatment with yohimbine (15 mg/kg/day) caused 
attenuation of the alpha-methylnoradrenaline induced pressor 
response with the dose required to increase the MAP by 50 
mmHg increased from 16 + 4 to 42 + 15 ug for control and 
treated groups, respectively. The dose response curve was 
shifted to the right with a dose ratio of 2.6 (figure 4.3).
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4.3.3 Effects of antagonists treatment on 
intracisternal clonidine injection.
Intracisternal administration of clonidine 1 ug/kg 
caused a prolonged fall in blood pressure and heart rate in 
control ascorbate treated rabbits with the maximum fall 
occurring at between 5 and 15 minutes after injection.
Chronic treatment with idazoxan (1.1 mg/kg/hr) 
attenuated the fall in blood pressure induced by clonidine 
injection. This was significantly (p < 0.05) different when 
compared to the control group at 15, 30 and 45 minutes
(figure 4.4). Treatment with yohimbine 15 mg/kg/day also 
attenuated the depressor response and was significantly (p 
< 0.05) different from controls at 5, 15, 30, and 45 minutes 
(figure 4.5). There were no significant treatment effects of 
the antagonists on the heart rate effects of clonidine.
4.3.4 Effects of treatments on m  vxtro [ H]Yohimbine 
and [^H]Idazoxan binding.
The treatment with yohimbine 15 mg/kg/day caused 63% 
and 103% increases in [^H]yohimbine binding to the forebrain 
and kidney membranes, respectively. These increases in Bmax 
were significantly different (p < 0 . 0 2  and p < 0 .0 0 2 ) when 
compared to the respective control groups. There was no 
significant treatment effect on the hindbrain (figure 4.6) 
nor was the KD significantly altered by yohimbine treatment 
(Table 4.1). [^ H]Idazoxan binding to kidney membrane was
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Effects of chronic yohimbine 15 mg/kg/day treatment on 
pressor r e s p o n s e s  to b o l u s  d o s e s  of a l p h a -  
methylnoradrenaline .
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significantly (p < 0.001) decreased by 52%. This decrease in 
Bmax was accompanied by a significant (p < 0.04) reduction 
in the KD. There were no significant changes in [^H]idazoxan 
binding to the forebrain or hindbrain membranes and no 
significant changes in KD were observed as a result of 
yohimbine treatment (figure 4.7 and Table 4.1).
Chronic idazoxan infusion 1.1 mg/kg/hr caused a 
significant (p < 0 .0 0 1 ) increase in the n u m b e r  of
[ H] yohimbine binding sites (Bmax) by 83% in the forebrain 
with no significant treatment effect on the hindbrain or 
kidney (figure 4.8). There was no significant treatment
•3
effect on the KD for [H]yohimbine binding m  any tissue
"3 ,
examined (Table 4.1). [ H ] I d a z o x a n  binding to kidney
membranes was significantly (p < 0.001) decreased by 89% 
after chronic 1.1 mg/kg/hr idazoxan infusion (figure 4.9). 
This was accompanied by a significant decrease in KD . No 
change in the number of binding sites was observed in the 
forebrain or hindbrain. There was a significant increase (p 
< 0.04) in the KD of [^H] idazoxan binding to the forebrain 
in the group treated with idazoxan (Table 4.1).
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Effects of chronic idazoxan 1.1 mg/kg/hr infusion on the 
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TABLE 4.1
Effects of yohimbine and idazoxan treatments on the dissociatio: 
constant (KD) nM for [3 H]yohimbine and [3 H]idazoxan binding.
[3 H]Yohimbine , [^H]Idazoxan
forebrain hindbrain kidney forebrain hindbrain kidney
Control 8 ± 3 12 + 3 15 + 8 4 + 3 3 + 2
+ 
1 4
Idazoxan 15 ± 6 10 + 4 12 + 4 7 + 4* 4 + 2 5 + 2 * *
Control 8 ± 2 11 + 5 8 + 4 4 + 2 3 + 2 4 ± 2
Yohimbine 13 ± 7 11 + 6 16 + 7 4 + 2 4 + 2 2 ± 1 * *
Result: mean ± s• D, * P < 0.05, ** p < 0.
i—1o n = 8 - 12
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4.4 DISCUSSION.
Studies on the pharmacological effects of alpha-
adrenoceptor antagonists have been limited by the relatively
low alpha 2 /alpha^-adrenoceptor selectivity and specificity
of the antagonists available until yohimbine and rauwolscine
were introduced (Tanaka et al., 1978; Weitzel et al., 1979;
Motulsky et al., 1980; Yamada et al., 1980). These drugs
were shown to be more selective and specific for alpha 2 _
adrenoceptors compared to other alpha2 ~antagonists available
then (Bylund, 1981; Bylund and U'Prichard, 1983). Recently,
idazoxan has been proposed to be a potent and highly
selective antagonist at alpha 2 ~adrenoceptors (Dettmar et
al., 1983; Doxey et al., 1983). However, idazoxan has been
shown to bind to non-adrenergic as well as adrenergic sites
(Coupry et al., 1987; Lachaud et al., 1988; Yablonsky et
al., 1988). In this Chapter (4), studies to compare effects
of acute and chronic infusions of idazoxan and yohimbine on
3alpha2 ~adrenoceptor mediated effects and on [ H] yohimbine 
and [3 H]idazoxan binding sites were reported.
Idazoxan infusion attenuated the pressor responses 
induced by i n t r a v e n o u s  i n j e c t i o n  of a l p h a -  
methylnoradrenaline and caused rightward shifts of dose 
response curves with dose ratios of 1.3 and 1.6 for acute 
dosing with idazoxan 0.56 and 1.1 mg/kg/hr while chronic 
treatment with 1 . 1  mg/kg/hr shifted the curves with a dose 
ratio of 2.0. Pretreatment with yohimbine also attenuated 
the hemodynamic effects of the alpha2-adrenoceptor agonist
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alpha-methylnoradrenaline with a rightward shift in the dose 
response curves and a dose ratio of 2 . 6  which is comparable 
to that observed with chronic idazoxan 1 . 1  mg/kg/hr 
infusion. These results are consistent with yohimbine and 
idazoxan acting as alph^-receptor blockers (Tanaka et al., 
1978; Weitzell et al., 1979; Dettmar et al., 1983).
Intracisternal injection of clonidine induces a 
depressor response (Reynoldson et al., 197 9; Hannah et al., 
1983), which has been shown to be mediated via the 
stimulation of central alpha2 ~adrenoceptors (Schmitt et al., 
1967; Dollery and Reid, 1973; Haeusler, 1974; Kobinger, 
1978) . These receptors are believed to be postsynaptic 
(Haeusler, 1974; Bousquet and Schwartz, 1983) and are 
located principally in the medulla oblongata (Schmitt and 
Schmitt, 1969). The depressor response induced by clonidine 
injection can be attenuated or abolished by treatment with 
alpha2 ~adrenoceptor antagonists (Bolme et al., 1 974; 
Timmermans et al., 1981; Hannah et al., 1983). Pretreatment 
with yohimbine and the higher dose of idazoxan (1 . 1  
mg/kg/hr), significantly antagonised the hypotension induced 
by intracisternal injection of clonidine, consistent with 
the drugs roles as a l p h a 2 _ a d r e n o c e p t o r  blockers.
In the radioligand binding experiments, the increase in 
[3 H]yohimbine binding in the forebrain and kidney after 
chronic yohimbine treatment plus the increase in binding to 
the forebrain after chronic 1 . 1  mg/kg/hr idazoxan infusion 
is also consistent with the alpha2-adrenoceptor antagonist 
properties of these drugs (Doxey et al., 1984; Weitzell et
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al., 1979; Doxey et al., 1983; Dettmar et al., 1983; Hannah 
et al., 1983). Up-regulation in both alpha- and beta- 
adrenoceptors has been reported after chronic administration 
of adrenergic receptor antagonists and noradrenergic 
terminal destruction or depletion in animals (U'Prichard 
and Snyder, 1978; U'Prichard et al., 1979; Johnson et al., 
1980; Davies and Lefkowitz, 1981). The reason for the 
localized up-regulation in [H]yohimbine binding sites as a 
result of treatment is not known, and the effect of chronic 
treatment on receptor number appeared to depend on the brain 
region examined. The pre- and postsynaptic location of the 
receptor, the density of innervation and the alpha2 - 
adrenoceptor subtype predominating in that region may all be 
contributory factors. In addition selective accummulation of 
drug in different brain regions could modify the receptors 
in that area specifically. Tissue and drug specific changes 
in adrenoceptor binding have been observed centrally and in 
the periphery by others (Sporn et al., 1976; Winter et al., 
1986; Minneman et al., 1981). In contrast to the expected 
effects of a n ta go n is t s  on rec e pt or  b i n d i n g  sites, 
[3 H]idazoxan binding to kidney membranes was significantly 
reduced by pretreatment with yohimbine and idazoxan. The 
reductions were accompanied by significant decreases in KD. 
These observations are very hard to reconcile with the 
action of these drugs as alpha2~adrenoceptor antagonists. 
However, idazoxan has been reported to have partial agonist 
properties (Hannah et al., 1 983). Consistent with this
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observation, chronic treatment with beta-adrenoceptor 
antagonists with partial agonist activity have been shown to 
cause down-regulation of beta-receptors (Giudicelli et al., 
1984; Brodde et al., 1986b; Neve and Molinoff, 198 6 ).
Idazoxan has been reported to bind to a non-adrenergic 
receptor site (Bricca et al., 1988; Wikberg 1988; Yablonsky 
et al., 1988), it is therefore possible that both yohimbine 
and idazoxan may be acting as agonists on this site in the 
periphery thus causing down-regulation. However, most drugs 
showing a higher affinity for the idazoxan binding site are 
imidazol (in) es or with related structures. Yohimbine does 
not have an imidazole structure and showed a low affinity for 
the [^H]idazoxan site in in. vitro displacement studies 
(chapter 3) . It is possible that yohimbine is acting 
indirectly to cause down-regulation of the idazoxan site. 
Both yohimbine and idazoxan treatment resulted in a reduction 
in Kd for [3 H]idazoxan binding suggesting that these
compounds are not simply down-regulating the binding site. A
3 . .small but significant increase in KD of [JH]idazoxan binding
was observed in the forebrain after idazoxan treatment. The
reason for this is unknown. H o w e v e r  the level of
significance was low and it may be unwise to attribute
biological significance to this single result.
In conclusion, in the in vivo functional studies both 
idazoxan and yohimbine behaved as expected for alpha2- 
adrenoceptor antagonists. In contrast anomalies were 
observed in the radioligand binding studies, no changes in 
the number of idazoxan binding sites were observed in either
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forebrain or hindbrain during yohimbine or idazoxan 
treatment, while [ ] yohimbine binding sites in the
forebrain but not in the hindbrain were significantly 
increased by both idazoxan and yohimbine treatments. In the 
kidney, ■ [ H]yohimbine binding sites were significantly 
increased by y o h i m b i n e  but not i d az ox an  t r e a t m e n t
r>
but [ H]idazoxan binding was significantly decreased by both
yohimbine and idazoxan treatments. Thus idazoxan and
yohimbine binding sites can be differentially regulated,
which further supports the hypothesis that the site lablled
by idazoxan is distinct from the alpha 2 -adrenoceptor site 
■3
labelled by [H]yohimbine.
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CHAPTER FIVE
EFFECTS OF CHRONIC AMITRIPTYLINE ALONE OR IN COMBINATION 
WITH IDAZOXAN OR YOHIMBINE ON CENTRAL ADRENOCEPTORS IN THE
RABBIT.
5.1 INTRODUCTION.
Research into the mechanisms of action of psychotropic 
drugs has largely been responsible for the development of 
the hypotheses implicating monoamine deficiency in 
depression. These hypotheses are based on the observations 
that monoamine depleting agents such as reserpine can 
produce clinical depressive states in humans while 
clinically effective antidepressants of the tricyclic and 
monoamine oxidase inhibitors (MAOIh classes act rapidly to 
enhance the synaptic concentration of amines and serotonin 
in brain (Schildkraut, 1965; Bunney, 1965; Charney et al., 
1981; Stahl, 1984). Many investigators measured monoamine 
metabolites such as 3-methoxy-4-hydroxyphenethyleneglycol 
(MHPG), a noradrenaline metabolite, and 5-
hydroxyindoleacetic acid (5-HIAA), a 5-HT metabolite in the 
urine, plasma and cerebro-spinal fluid (CSF) of depressed 
patients before and after administration of antidepressant 
drugs (Dekirmenjian and Maas, 1974; Maas et al., 1976; 
Ursillo et al., 1980). These studies failed to identify 
metabolic disorders of biogenic amine metabolites in the 
untreated depressed patients as a group (Stahl, 1984;
Charney et al., 1981). However, one finding was that some 
patients with low CSF 5-HIAA concentrations may be prone to
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suicidal attempts (Stanley et al., 1982). Hence, biogenic 
amine metabolites have not been useful in identifying a 
biochemical abnormality in depressed patients. The 
importance of increased availability of synaptic monoamines 
as a necessary and sufficient mechanism for antidepressant 
effects has been questioned increasingly for several reasons 
(Sulser et al., 1978). The tricyclic antidepressants 
blockade of noradrenaline and / or serotonin uptake is 
rapid yet a lag phase of one to three weeks exists before 
the onset of a clinical amelioration: furthermore atypical 
antidepressants such as iprindole (Gluckman and Baum, 1969; 
Lahti and Maichel, 1971) and mianserin (Leonard, 1974; 
Goodlet et al., 1977) are essentially devoid of effects on 
monoamine uptake _in vivo yet are effective antidepressants 
(Zis and Goodwin, 1979). Lastly, effective amine uptake 
inhibitors such as amphetamine, femoxetine and cocaine 
appear not to be useful in the treatment of depression 
(Overall et al., 1962; Post and Goodwin, 1974; Ghose et 
al., 1977). The tricyclic antidepressants are however widely 
employed in the treatment of depression although it has 
not been possible to identify a common mode of action for 
this class of drugs (Charney et al., 1981).
Recently, neurochemical events which occur with 
approximately the same time course as antidepressant effects 
have been d e s c r i b e d  (Enna et al., 1981). Chronic 
administration of tricyclic antidepressants (2-3 weeks) has 
been associated with changes in beta-adrenoceptor number in 
rat brain (Banerjee et al., 1977; Bergstrom and Kellar,
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1979; Campbell et al., 1979; 1984; Keith et al., 1988). The 
down-regulation is accompanied by a loss in sensitivity of 
adenylate cyclase to stimulation by noradrenaline or 
isoproterenol (Sulser, 1978; Enna et al., 1981; Richardson 
and Hertz, 1983; Campbell et al., 1984). These observations 
on the pharmacological effects of chronic antidepressant 
treatments have led to the suggestion that the therapeutic 
effect of antidepressants is due to a progressive 
desensitization of central beta-adrenoceptors (Sulser, 1979) 
and evolved into the "neurotransmitter receptor" hypothesis 
of antidepressant action which postulates that adrenergic 
and / or serotonergic receptors are responsible for 
mediating the clinical effects ©f antidepressant drugs 
(Charney et al., 1981; Stahl, 1984).
The down-regulation of beta-adrenoceptors observed 
after chronic antidepressant treatment may be due to an 
increased synaptic concentration of biogenic amines (Wolfe 
et al., 1978; Sugrue, 1983). An increase in the amount of 
noradrenaline release per nerve impulse during chronic but 
not acute antidepressant treatment has been observed in the 
peripheral nerves (Crews and Smith, 1978). The increase in 
release may be due to adaptive changes which must occur 
before subsensitivity of postsynaptic beta-adrenoceptor 
manifests itself. The alpha2-adrenergic receptors located 
presynaptically on n o r a d r e n e r g i c  n e u r o n s  and  on 
noradrenergic cell bodies of the locus coerelus have been 
proposed to become desensitized upon chronic antidepressant
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treatment (Svensson and Usdin, 1978). The desensitization 
would lead to increased catecholamine release (Hughes, 
1978). Thus, down-regulation may result from initially 
increased neurotransmitter (agonist) levels leading to 
desensitization in which the receptor becomes uncoupled from 
adenylate cyclase system followed by a second irreversible 
stage in which the receptors become internalized. However, 
while down-regulation of beta-adrenoceptors is a consistent 
observation with antidepressant drug treatment, not all of 
these drugs have been shown to i nc rease s ynaptic 
noradrenaline levels. Down-regulation is therefore seen as a 
compensatory reaction to increased agonists levels. 
Alternatively, down-regulation may take place via a process 
independent of increased agonist (catecholamine) levels. 
This implies that the action of antidepressant drugs is to 
reduce the activity of beta-adrenoceptor mediated neuronal 
pathways directly (Susler, 1979; Charney et al., 1981; 
Sugrue, 1983; Maj et al., 1984).
Although, most reports suggested that the beta- 
adrenoceptors down-regulate, the effects of antidepressants 
treatment on alpha-adrenoceptor numbers have been diverse 
with reports of up-regulation and no changes in receptor 
number (Charney et al., 1981; Asakura et al., 1982; Vetulani 
et al., 1984; Stahl and Palazidou, 1986; Finberg, 1987). 
However, desensitization of alpha2~presynatic receptors has 
been demonstrated following chronic treatment of rats with 
imipramine or desipramine. A r e du ct i on  in a l p h a 2  - 
adrenoceptor sensitivity has been invoked to explain the
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enhanced release of catecholamines by desipramine (Crews and 
Smith, 1978; Svensson and Usdin, 1978) and reduced binding 
of alpha2 ~adrenoceptor ligands to cerebal cortical membranes 
from rats treated chronically with MAOI and tricyclic 
antidepressant has been reported (Smith et al., 1981; Cohen 
et al., 1982). The antidepressant effects were proposed to 
correct a pre-existing defect where alpha 2 -presynaptic 
receptor number is enhanced in depression and a reduction is 
observed after antidepressant treatment. These reports have 
therefore indicated that alpha 2 -adrenergic receptors may 
also be involved in therapeutic effects of antidepressants.
Since increases in catecholamine concentrations at the 
synapses has been indicated as an important aspect of 
antidepressant therapy and also as a prerequisite to 
reduction in beta-adrenoceptor function, desensitization of 
alpha2 ~adrenoceptor (presynaptic) could be a rate limiting 
step in the efficacy of antidepressant therapy. It was then 
proposed that coadministration of alpha£-adrenoceptor 
antagonists would result in a more rapid antidepressant 
response and the d o w n - r e g u l a t i o n  of central beta- 
adrenoceptors would be enhanced and accelerated (Crew et al., 
1978; Johnson et al., 1980; Wiech and Ursillo, 1980). 
Consistent with this hypothesis are several studies which 
have demonstrated that beta-adrenoceptors down-regulation is 
indeed enhanced and accelerated after coadministration of 
antidepressants with alpha2-receptor antagonist in rat brain 
(Scott and Crews, 1983; Salama et al., 1983; Campbell et al.,
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1984/ Keith et al., 1988).
Most of the experiments described above report changes 
in rat brain alpha2 ~ and beta-adrenoceptor number. However, 
marked differences in alpha 2 ~receptors between rodents and 
other species have been reported. In this chapter (5) 
effects of chronic amitriptyline either alone or in 
combination with yohimbine or idazoxan on a non-rodent 
species, rabbit, were studied. Idazoxan in addition to its 
reported alpha2 ~adrenoceptor antagonist property (Doxey et 
al., 1983; Dettmar et al., 1983)* has been reported to 
possess some antidepressant effect (Stahl and Palazidou, 
1986). Effects of these treatments on idazoxan and yohimbine 
binding sites in addition to beta-adrenoceptor numbers in 
rabbit brain were examined.
5.2 METHODS.
5.2.1 Drug administrations.
Male New Zealand white rabbits (2.5-3.00 kg) from 
Cheshire Rabbit Farm Ltd were used for all the studies. Six 
treatment groups of animals (n = 8 - 1 2 ) were studied: one 
group of rabbits was treated with amitriptyline 30 mg/kg/day 
intraperitoneally for 6 or 2 1  days ( 1 0  mg/kg tid), one group 
received combined amitriptyline (30 mg/kg/day) and yohimbine 
(15 mg/kg/day) for 6 days (I.P). While a third group 
received idazoxan (0.56 mg/kg/hr) intravenously via osmotic 
minipumps and amitriptyline (30 mg/kg/day) (I.P). Control 
groups received 0 .1 % ascorbate for either 6 or 2 1  days as
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appropriate. The effects of yohimbine treatment alone was 
studied in the previous chapter (4) . However the dose of 
idazoxan use for this study was lower than the dose studied 
in chapter four.
5.2.2 Tissue preparation.
At the end of the experimental period rabbits were 
killed with an overdose of pentobarbitone sodium and the 
brain tissue removed and prepared as described in methods 
section 2.4.1.
5.2.3 Receptor binding assays.
Radioligand binding assays were performed using 
[3 H] idazoxan (0.5-20.0 nM), [3 H] yohimbine (1.25-37.5 nM) and
[3 H] dihydroalprenolol (0.15-7.2 nM) for beta-adrenoceptors. 
Incubations were carried out as described in section 2.4.2 
of the Methods.
5.2.4 Data analysis.
Differences between groups were examined using unpaired 
t-test for the two groups treated for 2 1  days while 
analysis of variance was used for the three groups treated 
for 6 days.
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5.3 RESULTS.
5.3.1 Effects of 21 days amitriptyline treatment.
Twenty one days amitriptyline treatment significantly 
reduced the number of [3 H]yohimbine binding sites (Bmax) in 
the hindbrain by 54% (p < 0.01) but not in the forebrain 
(figure 5.1). The reduction observed in the hindbrain was as 
a result of changes in Bmax rather than changes in the 
affinity since no significant change in the KD was observed 
(Table 5.1). There was no significant treatment effect on 
either the Bmax or KD of the [ H] idazoxan binding site m  
forebrain or h i n d b r ai n  (figure 5.2); n e i t h e r  was 
[ H] dihydroalprenolol binding to either fore or hindbrain
significantly affected by treatment (figure 5.3). Although
3 . . .[H]yohimbine binding to hindbrain was significantly reduced
by 2 1  days treatment with amitriptyline, 6 days treatment 
had no significant effect (Bmax were 100 +_ 15 and 90 _+ 11 
fmoles/mg p r o te i n  for control and t r e a t e d  groups 
respectively).
5.3.2 Effects of J5 days coadministration of 
amitriptyline with yohimbine or idazoxan.
Coadministration of amitriptyline with either yohimbine 
or idazoxan had no significant treatment effects on either 
[3 H]idazoxan or [ 3 H]yohimbine binding in the forebrain or 
hindbrain (figures 5.4 and 5.5). There was no significant 
changes in KD of [3 H]idazoxan binding to forebrain or
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hindbrain also there was no significant treatment effect on 
the Kp for [ H]yohimbine binding in either brain region 
(Table 5.1). Coadministration of amitriptyline with either 
yohimbine or idazoxan did not significantly affect
r>
[ H]dihydroalprenolol binding sites in either brain regions 
(figure 5.6) and the KD was unchanged (table 5.1). However, 
there was a slight decrease in the forebrain but this did 
not reach statistical significance.
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TABLE 5.1
Effects of 21 days amitriptyline either alone or in combination with 
yohimbine or idazoxan on the dissociation constant KD (nM).
Kd (nM)
[^H]Yohimbine [^H]Idazoxan [^H]DHA
FB HB FB HB FB HB
Control 8 + 3 8 + 4 3 + 1 5 + 3
CSJ 
x—
1 +
ooO O 
x—
1 +
00o
Amitriptyline 1 1 + 3 7 + 4 4 + 2 4 + 3 1 . 1 + 0.9 o 00 + 0 . 2
Control 8 + 2 13 + 5 4 + 1 3 + 2 1 . 2 + 0.3
00o + 0 . 2
Amt +  Yoh 1 0 + 3 7 + 4 3 + 2 5 + 2 1.7 +
COo
1 . 0 + 0.7
Amt +  Idaz 8 + 4 1 0 + 6 5 + 2 4 + 2
<y\X—1 + 1.4 0 . 6 + 0.4
Results: mean + S.D, n = 8 - 12.
FB = forebrain, HB = Hindbrain, A m t  = amitriptyline, Yoh 
yohimbine, Idaz = idazoxan.
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5.4 DISCUSSION.
Chronic drug treatment can lead to modifications in 
receptor sensitivity which appears to be one of the means by 
which synaptic transmission is regulated. Long term receptor 
activation or blockade in vivo has been reported to lead to 
receptor desensitization or super^ensitization (Creese and 
Sibley, 1981; Davies and Lefkowitz, 1981; Lefkowitz et al.,
1983). Investigations into the comparative effects of acute 
and chronic antidepressant treatment on the turnover of 
brain monoamines in rats has led to the suggestion that the 
chronic administration of antidepressants initiates an 
adaptive process which could result in enhanced transmitter 
release (Shildkraut et al., 1970; 1971; Campbell et al.,
1979) and a reduction in the number of beta-adrenoceptor, 
these changes may be responsible for the mechanisms of 
action of the antidepressants. This hypothesis has been 
supported to a certain degree by the observation that 
chronic and not acute antidepressant treatment leads to 
clinical alleviation of depression (Denber, 1975; Charney et 
al., 1981; Sugrue, 1983).
In the experiments described here, 21 days of 
amitriptyline treatment significantly reduced the number of 
[^H] yohimbine binding sites in the hindbrain but not in the 
forebrain. The reduction was as a result of a reduction in 
Bmax and not as a result of a reduction in affinity since 
the K d was not significantly affected by the treatment. 
The reduction observed in the [ H]yohimbine binding is
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consistent with the postulate that alpha 2 -adrenoceptor 
sensitivity and possibly number will be reduced as a 
consequence of increased catecholamine concentrations in the 
central n e r v o u s  s y s t e m  c a u s e d  by the a c t i o n s  of 
antidepressants (Crews and Smith, 1978; Svensson and Usdin, 
1978). Consistent with this observation is the reduction in 
the binding of alpha 2 ~adrenoceptor ligands to cerebral 
membranes from rats treated chronically with both tricyclic 
and monoamine oxidase inhibitor antidepressants (Smith et 
al., 1981; Cohen et al., 1982). However, the reason for the 
localized reduction in [JH]yohimbine binding after 
amitriptyline treatment is not known, but penetration of the 
drug into the CNS and concentration in localized areas, 
pharmacokinetic interactions, receptor susceptibility to 
changes, and the receptor population predominating in this 
region could partially explain this observation. In support 
of this localized decrease in [ H]yohimbine binding is the 
finding that chronic amitriptyline lowers [H]clonidine 
binding in rat limbic structures (Crews and Smith, 1978) 
with no changes in binding to cortical slices (Peroutka and 
Snyder, 1980; Tang et al., 1981; Sugrue, 1982; 1983). In 
addition Scott and Crews, (1983) have reported localized 
changes in beta-adrenoceptors in rat brain after treatment 
with desipramine. In other studies, the number of alpha 2 - 
receptors in the CNS has been shown to be increased or 
decreased after antidepressant treatment (Creese and Sibley, 
1981; Finberg, 1987), and the direction of the change in 
alpha2 ~adrenoceptor n u m b e r  a p p e a r s  to d e p e n d  on the
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duration, and dose of drug administration and the brain 
region exa m i n e d  (Smith and Hollingsworth, 1984) plus 
concentration of noradrenaline in that region. The type of 
ligands, agonist or antagonist used in the studies has also 
been reported to affect the direction of change in alpha-
receptor numbers (Salama et al., 1983). However, a reduction
3 3m  [ H ] c l o n i d m e  and [ JH]yohimbine binding to cortical
membranes after chronic clorgyline treatment has been
reported (Cohen et al., 1982). In contrast to the changes
m  [H]yohimbine binding there was however no significant
treatment effect on [ H]idazoxan binding sites and KD m
either forebrain or hindbrain after 2 1  days amitriptyline
treatment. Differences between yohimbine and idazoxan could
relate to their binding to different sites (chapter 3).
The coadministration of amitriptyline with either
yohimbine or idazoxan did not have any significant effect on 
3 . 3 .[H]yohimbine or [H]idazoxan binding sites m  forebrain or
hindbrain. Also there were no significant changes observed
3 3in the Kd of both [H]idazoxan and[H]yohimbine binding m
either brain region examined. This observation is not
consistent with the postulated reduced alpha2 -adrenoceptor
sensitivity after tricyclic antidepressant treatment
(Finberg, 1987). In addition, there was a trend towards a
reduction in [ H]yohimbine binding m  the group treated with
combined yohimbine and amitriptyline. It is possible that a
longer duration of treatment or higher doses of both
yohimbine and amitriptyline could lead to reduction in the
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number of binding sites. Changes in alpha 2 -adrenoceptor 
number have b e e n  o b s e r v e d  by s o m e  g r o u p s  a f t e r  
coadministration of antidepressants with alpha2 ~adrenoceptor 
antagonists. Ursillo et al. (1980) reported an increase in 
[ H]para-aminoclonidine binding sites in cerebral cortex 
after four days desipramine and yohimbine treatment.
In the experiments involving treatment with either 
yohimbine or idazoxan alone it was observed that both 
treatments s i g n i f i c a n t l y  i n c r e a s e d  the n u m b e r  of
3
[H]yohimbine binding sites in the rabbit brain (chapter 3). 
Hence, in these studies, it seems that the coadministration 
of antagonists with amitriptyline may be having opposing 
effects with amitriptyline increasing the biogenic amines 
(agonists) concentration leading to down-regulation while 
the antagonists up-regulates. This could be responsible for 
the lack of change in receptor number in this experiment.
3 ,
In these studies, [ H]dihydroalprenolol binding was not 
significantly affected by treatment with amitriptyline 
either alone or in combination with yohimbine or idazoxan. 
Although there was a slight reduction in groups treated with 
amitriptyline in combination with yohimbine or idazoxan, 
this did not reach significance. In contrast to these 
observations in rabbit, numerous groups have reported 
decreases in [ H ]DHA binding in rats after tricyclic 
antidepressant treatment with an increase in the extent and 
rate of decrease when the antidepressant was given in 
combination with an alpha 2 _adrenoceptor antagonist. Wiech 
and Ursillo (1980) and Charney et al. (1986) reported a
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significant reduction in [^HJDHA binding to cerebral cortex 
after 4 days and 6 days treatment with desipramine, 
respectively. A l s o  a s i g n i f i c a n t  d e c r e a s e  in b e t a -  
adrenoceptor number has been reported in the cortex by 
Minneman et al. (1982) after 10 days desipramine treatment. 
In contrast, Ursillo et al. (1980) were only able to observe 
a significant reduction in the number of [^HJDHA binding 
sites after 42 days when desipramine alone was used. The 
administration of imipramine alone was reported by Keith et 
al. (1988) to cause progressive reduction in the number of
“3
[ H]DHA binding reaching m a x i m u m  after four weeks of 
treatment in rat cerebral cortex. While coadministration of 
imipramine with alpha2 ~adrenoceptor antagonists resulted in 
accelerated down-regulation of beta-adrenoceptor with 
maximum reduction occurring only after one week of 
treatment. It is however, possible, that changes in beta- 
adrenoceptor number in the rabbit brain may occur in 
localized areas and were not detected in this study. In 
addition, longer treatment or higher doses of drugs may 
result in a significant reduction in receptor number. 
[ H]DHA has a similar affinity for both beta-^- and beta 2 _ 
adrenoceptors and subtype selective down-regulation may have 
occurred which was not detected in this experiment. Minneman 
et al. (1978; 1982) have reported selective regulation of 
beta^- and beta 2 ~adrenoceptors while Beer et al., (1987) 
also reported independent regulation of beta-^- and beta 2 ~ 
adrenoceptors in rats after treatment with desipramine. In
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addition, amitriptyline treatment may have greater effects 
on muscarinic cholinergic receptors (Rehavi et al., 1980) 
and serotonin transport / uptake (Koe, 1976) than 
noradrenaline uptake and beta-adrenoceptors. However, these 
results emphasise the danger of generalising from findings 
with receptor binding experiments done across tissues and 
species and suggest that beta-adrenoceptor down-regulation 
may not be a universal response to tricyclic antidepressant 
treatment.
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CHAPTER SIX
CHRONIC INTRACEREBROVENTRICULAR INFUSION OF ADRENALINE AND 
NORADRENALINE: EFFECTS ON CENTRAL ADRENOCEPTORS IN THE
RABBIT.
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CHAPTER SIX
EFFECTS OF CHRONIC INTRACEREBROVENTRICULAR INFUSION OF
ADRENALINE AND NORADRENALINE ON CENTRAL ADRENOCEPTORS IN THE
RABBIT.
6 .1 INTRODUCTION.
The effects of acute and chronic catecholamine exposure 
on peripheral alpha- and beta-adrenoceptors have been 
extensively studied (Mickey et al., 1975/ Perkins, 1981; 
Maura et. al., 1985; Jones et al., 1986; Neve and Molinoff, 
1986; Deighton et al., 1 98 6 ; 1 98 8 ), but for technical
reasons very few studies have looked directly at the effects 
of chronic changes in central catecholamine levels on 
central adrenoceptors. Investigators have, however, employed 
various methods of altering central catecholamine levels 
indirectly by administration of drugs which influence the 
levels of adrenaline and noradrenaline in the brain. Such 
drugs include tricyclic antidepressants and monoamine 
oxidase inhibitors which increase the synaptic concentration 
of the biogenic amines via inhibition of uptake mechanisms 
and degradation of catecholamines by monoamine oxidase, 
respectively (Gluckman and Baum, 1969; Cohen et al., 1980; 
Charney et al., 1981; Asakura et al., 1982; Sugrue, 1983; 
Campbell et al., 1 9 7 9 ). O t h e r  m e t h o d s  i n c l u d e  the 
destruction of central catecholaminergic pathways by the 
administration of 6 -hydroxydopamine or reserpine which 
deplete neuronal catecholamine storage (U'Prichard and 
Snyder, 1978; U'Prichard et al., 1979; Bylund and Martinez, 
1980; Hamilton and Reid, 1982). In addition to these
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treatments, treatment with alpha2 _adrenoceptor agonists and 
antagonists which readily cross the blood brain barrier have 
been u s e d  to s t udy r e g u l a t i o n  of c e n t r a l  a l p h a 2 - 
adrenoceptors. These include the imidazoline and guanidine 
groups such as c l o n i d i n e ,  i d azoxan, g u a n f a c i n e ,  
phentolamine, guanethidine, guanabenz and B-HT 933 (Oates et 
al., 1979; Timmermans and van Zwieten, 1980; Thoolen et al., 
1982; Maura et al., 1985; Finberg and Kopin, 1987). 
However, the effects of such treatments on central 
adrenoceptor function and density have been conflicting 
(Charney et al., 1981; Armstrong et al., 1983; Finberg, 
1987). In addition, all the drugs used in these studies have 
imidazole or related structures. The effects of direct 
injection of phenylethylamine and imidazole type of drugs 
into rostral ventrolateral medulla have been shown to differ 
and this has led to the suggestion that the two classes of 
compound may be acting at different sites (Bousquet et al.,
1984). Lack of cross-desensitization between these classes 
of drugs in the periphery has given support to this 
hypothesis (Ruffolo et al., 1 977-). Furthermore, it has 
recently been shown that clonidine and its analogue para- 
aminoclonidine, bind to sites distinct from alpha 2 - 
adrenoceptor sites and a low molecular weight substance
. 3  , , -3
which can displace [ H] clonidine and [ H] para-aminoclonidme 
from their binding sites has been isolated from bovine brain 
membrane (Atlas and Burstein, 1984; Ernsberger et al., 1986; 
Meeley et al., 1986; Felsen et al., 1987). More recently,
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idazoxan an imidazoline derivative has also been reported to 
bind with high affinity to a site distinct from the alpha 2 - 
adrenoceptor site (Coupry et al., 1987; Lachaud et al., 
1988; Wikberg, 1988; Yablonsky et al., 1988). Thus the 
effects of chronic treatment with imidazoline type of 
agonists may not reflect changes occurring during chronic 
elevation of the endogenous catecholamines adrenaline and 
noradrenaline.
Most of the studies reporting changes in a l p h a 2 ~ 
adrenoceptor function and number on chronic treatment with 
catecholamines have been carried out in the periphery while 
central regulation of alpha 2 ~adrenoceptors has not been
widely studied particularly in response to stimulation by
*
catecholamines. This has b e e n  due to the fact that 
peripherally administered catecholamines do not cross the 
blood brain barrier (Hardebo and Owman, 1980; Oldendorf, 
1971; Minneman, 1983). However, intracerebroventricular 
infusion has been described recently (Jefferies and 
Orzechowski 1985; Wu and Wei 1984; Correa et al., 1982; 
Johnson et al., 1987). This method has made it possible for 
direct drug infusion into the brain via the cerebral 
ventricle and it has been used to study the effects of some 
centrally acting drugs such as carbachol and saralasin 
(Brunner et al., 1983; Wu and Wei, 1984). This method has 
therefore be e n u s e d  to s t udy e f f e c t s  of c h r o n i c  
catecholamine infusion directly into the brain on functions 
mediated by alpha2 ~adrenoceptors and on densities of central 
adrenergic receptors in the rabbit.
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6.2 METHODS.
6.2.1 Doses and drug infusions.
Ten day infusions of adrenaline (100 ug/kg/hr) or 
noradrenaline (150 ug/kg/hr) were carried out in groups of 
rabbits (n = 6 - 8 ) . The dose of adrenaline infusion was 
reduced from 150 ug/kg/hr to 100 ug/kg/hr because in pilot 
studies, at the higher dose, some rabbits (3) died within 
24-36 hours of commencing infusion. Control groups studied 
in parallel received 0.1% ascorbate. Alzet osmotic minipumps 
(figure 2.1) model 2002 with a nominal flow rate of 0.5 
ul/hr were loaded with either the drug or vehicle. Drugs 
were infused continuously into the left cerebral ventricle 
via intracerebral cannulae implanted and held in place by a 
head plate as described in the methods section 2 .2 .2 .4.
6.2.2 Effects on intracisternal injection of clonidine.
To monitor effects of chronic catecholamine infusion on
alpha2 ~adrenoceptor m e diated function, the depressor 
response to intracisternal injection of clonidine ( 1 ug/kg) 
was examined in anaesthesized treated and control groups. 
Changes in mean arterial blood pressure (MAP) mmHg were 
monitored at intervals for 60 minutes (methods 2.3).
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6.2.3 Tissue preparation.
At the end of the blood pressure monitoring, rabbits 
were killed by an overdose of pentobarbitone sodium (60 
mg/ml) . The brain was removed and dissected into forebrain 
and hindbrain at the point of coliculli. The forebrain was 
then dissected into left and right cerebrum at the mid 
brain. The brain tissues were prepared by homogenization and 
centrifugation as d e s c r i b e d  in m e t h o d s  (2.4.1) for 
radioligand b i n d i n g  a s sa y s (2.4.2) and for t i s s u e  
catecholamine assay (methods 2 .6 ).
6.2.4 Radioligand binding assays.
In order to study effects of chronic catecholamine 
infusion on central adrenoceptors, radioligand binding 
experiments were performed using tissue homogenates and the 
ligands [^H]yohimbine (1.25-37.0 nM), [^H]idazoxan (0.5-20.0 
nM) and [ H] dihydroalprenolol (0.15-7.2 nM) as described m  
the methods section 2.4.2.
6.2.5 Data and statistical analysis.
Radioligand binding parameters and KD were obtained 
from modified Scatchard plot analysis (section 2.4.3). Bmax 
and K d for control, adrenaline and noradrenaline treated 
animals were then compared using one way analysis of 
variance. The differences between the depressor response to 
clonidine injection in catecholamine and vehicle treated
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groups were analysed by repeated measures analysis of 
variance w i t h  B o n f e r r o n i  c o r r e c t i o n  for m u l t i p l e  
comparisons.
6.3 RESULTS.
No significant changes in the mean arterial blood 
pressure and heart rate of the animals used in this 
experiment were observed throughout the period of drug 
infusion. Also, there were no obvious behavioural changes 
during the infusion.
6.3.1 Effects of catecholamine infusion on tissue 
catecholamine levels.
The effect of chronic catecholamine infusion on tissue 
catecholamine levels as assayed by HPLC-ECD is presented in 
table 6.1. There was variation within the groups in the 
levels of catecholamine assayed but the highest levels were 
consistently observed in the left cerebrum, the area into 
which the drugs were infused, with lower levels in the right 
cerebrum and h in d br ai n.  In the assay, a d r e n a l i n e  
concentrations in saline/ascorbate and noradrenaline infused 
rabbits, were below the level of detection, while groups 
that received either adrenaline or noradrenaline, showed 
higher levels of catecholamines with increases of 50 fold or 
greater in the left cerebrum and around 1 0  fold in the 
hindbrain during noradrenaline infusion. Although, the
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tissues were washed thoroughly, it is possible that not all 
perfusate was removed and this could have contributed to the 
high catecholamine levels observed in the left cerebrum.
6.3.2 Effects of clonidine injection (I.C).
Intracisternal clonidine injection (1 ug/kg) produced a 
prolonged depressor response with a maximum fall of -26 _+ 1 1  
mmHg at 15 minutes after the injection in the control group. 
Chronic adrenaline infusion 100 ug/kg/hr significantly 
attenuated the depressor response induced by intracisternal 
clonidine injection. The maximum fall was significantly 
reduced to -10 _+ 4 mmHg and was significantly attenuated 
when compared to controls at 5, 15 and 30 minutes after the
injection (figure 6.1). However, noradrenaline infusion did 
not have any significant effect in attenuating the fall in 
blood pressure induced by the clonidine injection (figure 
6.2). Neither of these treatments had significant effects on 
the heart rate changes induced by clonidine injection.
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Table 6.1
Effects of chronic intracerebroventricular infusion of catecholamines 
adrenaline and noradrenaline concentration (pm/mg protein) in th« 
rabbit brain tissues.
Treatments: Control Adrenaline Noradrenaline
NA ADR NA ADR NA ADR
Lt cerebrum 5 + 4  ND 1 4 + 5 360 + 441 430 +233 ND
Rt cerebrum 5 + 4 ND 2 2  + 2 2 85 + 40 128 + 1 0 1 ND
Hindbrain 4 + 4 ND 11 + 4 52 + 79 37 + 34 ND
Result:- mean + S.D, n = 6 - 8 .
ND = Not detectable, Rt = right, Lt = left. 
NA = Noradrenaline, ADR = Adrenaline.
146
6.3.3 Effects of chronic catecholamine infusion on:-
o
6 .3.3.1 [ H]Idazoxan binding sites.
Chronic a d r e n a l i n e  (100 u g / k g / h r )  i n f u s i o n  
significantly reduced the m a x i m u m  n umber (Bmax) of 
[ H] idazoxan binding sites from 55 + 9 to 33 + 9 fmoles/mg 
protein in the right cerebrum (figure 6.3). There was no 
significant treatment effect on the binding sites in either 
left cerebrum or hindbrain. Chronic noradrenaline infusion 
did not have any significant effect on [^H]idazoxan binding 
sites in any brain region examined (figure 6.4). There was 
no significant changes in the KD as a result of these 
treatments (Table 6.2).
"3
6 .3.3.2 [ H]Yohimbine binding sites.
Neither c h r o n i c  a d r e n a l i n e  (100 ug/kg/hr) nor 
noradrenaline (150 ug/kg/hr) had any significant effect on
-3 , ,
the maximum number (Bmax) of [JH]yohimbine binding sites m  
any of the brain areas studied (figures 6.5 and 6 .6 ). 
Although Bmax from the group that received adrenaline tended 
to be reduced (from 137 _+ 33 for control to 109 _+ 15 
fmoles/mg protein for adrenaline treated) this did not reach 
significant level. However, a significant increase in the 
dissociation constant (KD) was observed in both left and 
right cerebrum but not in the hindbrain with both adrenaline 
and noradrenaline infusions (Table 6.2).
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o
6 .3.3.3 [—H]Dihydroalprenolol binding sites.
Neither chronic adrenaline nor noradrenaline infusion 
had any significant treatment effects on either the binding 
sites or the affinity state of [^H]dihydroalprenolol binding 
at any of the brain regions studied (figures 6.7 and 6 .8 ) 
(Table 6.2).
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Figure 6.1
Effects of chronic adrenaline (100 ug/kg) infusion (icv) on 
the depressor response to intracisternal clonidine (lug/kg) 
injection.
_ _ Cont ro l
O ■o
Adrenaline
n = 6 - 8 , * P < 0.05.
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Figure 6.2
Effects of chronic noradrenaline (150 ug/kg) infusion (icv) 
on the depressor response intracisternal clonidine (lug/kg) 
injection.
_ _ Control
o ■o Noradrenaline.
n = 6 - 8 .
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Figure 6.3
Effects of chronic adrenaline (100 ug/kg) infusion on the 
number of [^H]idazoxan binding sites.
□ Control
Adrenaline 
n = 6 - 8 , * P <  0.05.
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Figure 6.4
Effects of chronic noradrenaline (150 ug/kg) on the number 
of [^H]idazoxan binding sites.
Control□
Noradrenaline 
n = 6 - 8 .
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Figure 6.5
Effects of chronic adrenaline (100 ug/kg) infusion on the 
number of [^H]yohimbine binding sites.
□ Control 
Adrenaline 
n = 6 - 8.
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Table 6.2
Effects of chronic c a t e c h o l a m i n e  infusion on the 
dissociation constant (KD) nM.
Treatments: Control Adrenaline Noradrenaline
[^H]Idazoxan
Rt cerebrum 2 + 1 3 + 1 3 + 2
Lt cerebrum 2 + 1 2 + 1 3 + 2
Hindbrain 2 + 1 3 + 1 3 + 1
[^H]Yohimbine
Rt cerebrum 8 + 3 13 + 3* 11 + 5*
Lt cerebrum 6 + 3 13 + 7* 13 + 5*
Hindbrain 8 + 5 8 + 5 10 + 4
*3
[JH]Dihydroalprenolol
Rt cerebrum 0.9 + 0.6 0.9 + 0.2 1.6 + 0.7
Lt cerebrum 1.0 + 0.6 1.0 + 0.2 1.5 + 0.5
Hindbrain 0.8 + 0.6 0.5 + 0.1 0.7 + 0.5
Results: mean •t si.D, * p < 0.05, n = 6 - 8.
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Figure 6 . 6
Effects of chronic noradrenaline (150 ug/kg) infusion on the 
number of [3 H]yohimbine binding sites.
U  Control
Noradrenaline 
n = 6 - 8.
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Figure 6.7
Effects of chronic adrenaline (100 ug/kg) infusion on the 
number of [^H]dihydroalprenolol binding sites.
□ Control
Adrenaline 
n = 6 - 8 .
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Figure 6 . 8
Effects of chronic noradrenaline (150 ug/kg) infusion on the 
number of [^H]dihydroalprenolol binding sites.
□ Control 
Noradrenaline 
n = 6- - 8 .
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6.4 DISCUSSION.
Intracerebroventricular infusion of catecholamines 
causes increased adrenaline and noradrenaline levels in the 
rabbit brain as assayed using HPLC-ECD methods (Hashimoto and 
Maruyama, 1977; Howes et al., 1983). The increases varied 
from 2 to more than 50 fold in the different brain regions 
when compared to the controls as shown in table 6.1. The 
highest concentrations of catecholamine being observed in 
the left cerebrum into which the-drug was infused. These 
results show that the method of infusion used was effective 
at delivering drug into the brain (Wu and Wei, 1984; 
Jefferies and Orzechowski, 1985; Johnson et al., 1987). 
However, contamination from the infusate could contribute to 
the high levels of catecholamines observed.
Chronic intracerebroventricular infusion of adrenaline 
but not noradrenaline significantly attenuated the depressor 
response induced by intracisternal injection of clonidine. 
In addition, adrenaline was more toxic as it caused death at 
150 ug/kg/hr before it was reduced to 1 0 0  ug/kg/hr while the 
same dose of noradrenaline had no obvious adverse effects. 
In the periphery, adrenaline but not noradrenaline has been 
reported to attenuate platelet aggregation and decrease 
receptor number while noradrenaline but not adrenaline 
decreased receptor number in the kidney (Brodde et al., 
1982; Deighton et al., 1986; Hamilton et al., 1987). These 
effects could be related to the subtype of a l p h a 2 ~ 
adrenoceptor found in platelets and kidney and the greater 
responses to adrenaline observed in these experiments could
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be related to the alpha 2 ~subtype predominating within the 
brain. The existence of alpha2 ~adrenoceptor subtypes between 
and within species has been widely reported (Neylon and 
Summers 1985; Bylund 1981; 1985; 1988). Bylund (1988)
reported that alpha 2 ~adrenoceptors on human platalets are 
exclusively of the alpha 2 ^~subtype. Alpha 2 A ~subtypes also 
predominate in rat cerebral cortex and submandibular gland 
and in human caudate nucleus, while neonatal rat lung has a 
high proportion of alpha 2 g subtype. In human cortex and 
cerebrum, the ratio of the alpha2 ^ to alpha2 g is 100;0. The 
subtype of receptor predominating in a region or tissue may 
determine the effects of drugs in that tissue. Adrenaline 
has a higher affinity for the alpha2 A ~subtype which occurs 
exclusively in platelets and predominates in many brain 
regions. Moreover, although both catecholamines have been 
implicated in the regulation of blood pressure (Kobinger, 
1978), it has been reported that adrenaline may be 
responsible for mediating sympathetic cardiovascular and 
baroreflex vasodepressor responses (Fuller et al., 1980; 
Granata et al., 1985; Ruggiero and Reis, 1988) and this is 
consistent with the greater effect of chronic adrenaline 
than noradrenaline in attenuating the depressor response to 
clonidine in these experiments.
No reduction in the number of [ H]yohimbine binding 
sites in the hindbrain was observed. However attenuation of 
response without loss in number may precede a down- 
regulation in number. In previous studies, chronic
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amitriptyline treatment in rabbits also caused attenuation 
of the clonidine depressor response without a change in 
number, but the attenuation was related to an alteration in 
affinity state of the receptor (Hamilton et al., 1986). In 
the forebrain there was a tendency towards a decrease in 
[ H]yohimbine binding and a longer infusion time or higher 
dose of infusion might lead to a significant decrease in the 
number of binding sites.
Alterations in t h e  d i s s o c i a t i o n  c o n s t a n t  of
•3
[ H] yohimbine binding to both the left and right cerebrum 
were observed after adrenaline and noradrenaline infusion. 
This could be due to agonist retention. Consistent with this 
observation was the r e p o r t e d  i n c r e a s e  in a p p a r e n t  
dissociation constant for [ JH] yohimbine with no change in 
Bmax after incubation of platelets with epinephrine 
(Karliner et al., 1982).
■3
Changes in [ H] yohimbine binding were less marked than 
has been reported for guanabenz (chapter 7) after 5 days 
infusion. Pharmacokinetic and pharmacodynamic properties plus 
metabolism of guanabenz may be different from that of 
catecholamines. In addition guanabenz could also have 
different affinities for subtypes of alpha2 ~receptor.
*3
The decrease in the number of [JH]idazoxan binding 
sites in the right cerebrum after adrenaline infusion was 
surprising as throughout this thesis no other treatment
•3
caused changes in the number of [JH]idazoxan binding sites 
in the brain, in addition, although adrenaline was infused 
via the left side of the brain no significant change was
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observed on this side. This result is therefore difficult to 
explain on physiological or pharmacological grounds. Taking 
a significant level of p < 0.05, one in 20 t-tests would 
give a false positive result, thus considering the number of 
comparisons made in this thesis, it would not be surprising 
if one outlying result is obtained which may not have any 
significant biological importance.
•3
No changes m  the number of [ H]dihydroalprenolol 
binding sites was observed in either the brain regions 
examined which is consistent with lack of change in density 
after amitriptyline treatment (Hamilton et al., 1986; 
Chapter 5) . In the rat, changes in the number of beta- 
adrenoceptors have been reported (Minneman et al., 1978; 
Ursillo et al., 1980; Beer et al'., 1986; Charney et al.,
1986). Rabbit beta-adrenoceptors may be more resistant to 
changes although Minneman (1983) also reported rat beta- 
adrenoceptors to be resistant to regulation.
In this study, the depressor response to clonidine 
injection (i.c) was attenuated by chronic adrenaline but not 
noradrenaline infusion although no changes in [JH]yohimbine 
binding were obtained, [H]idazoxan binding to the right 
cerebrum was reduced by adrenaline infusion but this may not 
be of any biological significance. Thus this study has 
demonstrated that receptor med i a t e d  functions may be 
regulated by chronic putative agonist treatment without 
meaningful changes in the density of receptor binding sites.
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CHAPTER SEVEN
EFFECTS OF CHRONIC GUANABENZ INFUSION ON RABBIT ALPHA2_ AND
IMIDAZOLE TYPE RECEPTORS.
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CHAPTER SEVEN
EFFECTS OF CHRONIC GUANABENZ INFUSION ON RABBIT ALPHAq- AND
IMIDAZOLE TYPE RECEPTORS..
7.1 INTRODUCTION.
Guanabenz, a guanidine derivative has been shown to have 
antihypertensive properties. Its mechanism of action is by 
stimulation of central a l p h a 2 - a d r e n o c e p t o r s , thereby 
reducing sympathetic outflow (Baum and Shropshire, 1976/ 
Ohata et al., 1982). Guanabenz lowers blood pressor and 
heart rate in both normotensive and hypertensive rats (Baum 
et al., 1970; Baum and Shropshire, 1976; Misu and Kubo, 
1982). It has been reported to reduce noradrenaline turnover 
in the brain (Braestrup and Nielsen, 1976) and to possess a 
diuretic, property (Strandhoy et al., 1 980). It has a 
pharmacological profile similar to that of clonidine (Baum 
et al., 1970; Baum and Shropshire, 1976). However, 
differences between guanabenz and clonidine's mechanisms of 
action have been reported. Gutkin and Enero (1983) have 
shown that the cardiovascular effects of clonidine but not 
guanabenz were antagonised by uptake blockers. In the 
periphery, guanabenz induced pressor effects in pithed rats 
via postsynaptic alpha 2 ~adrenoceptors while clonidine 
activated both vascular alpha-^- and alpha 2 ~adrenoceptors 
(Gutkin et al., 1986). Gutkin and Enero, (1987) further 
showed differences in the pharmacological interaction of 
clonidine and guanabenz with antidepressant drugs and 
postulated that these drugs might be acting on different 
receptors. It has been suggested that idazoxan may label a
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novel imidazole-like /idazoxan receptor (Yablonsky et al., 
1988; Bricca et al., 1988; Wikberg, 1988; Vigne et al., 
1989). In radioligand displacement experiments (chapter 3) 
guanabenz showed a high affinity (2.8 nM) for [ H] idazoxan 
binding sites while clonidine showed a relatively low 
affinity (800 nM) for the same binding site. Both drugs 
(clonidine and guanabenz) showed a similar but fairly low
*3 , .
affinity for the [ H]yohimbine binding site.
Chronic agonist treatment may lead to receptor down 
regulation and desensitization. The effects of acute and 
chronic clonidine treatment on receptor number and function 
have been a subject of extensive study (Reid et al., 1977; 
Brodde et al., 1982; Maura et al., 1985; Finberg and Kopin, 
1987), but the effects of chronic guanabenz treatment on 
alpha2 -adrenoceptor number and function have not been as 
widely studied and may differ from those of clonidine. In 
previous studies, treatment of hypertensive patients with 
guanabenz did not lead to changes in platelet alp h a 2 ~ 
adrenoceptor (Motulsky et al., 1983) but Brodde et al., 
(1982) reported reduced platelet alpha2 ~adrenoceptor number 
in patients treated with clonidine. This chapter (7) is 
therefore aimed at examining effects of chronic guanabenz
treatment on alpha2 ~adrenoceptor mediated function and the
3 . 3effects of treatment on the [JH]yohimbine and [H]idazoxan
binding sites in rabbit brain and kidney membranes.
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7.2 METHODS.
The experiments were performed using groups (n = 6 - 9) 
of rabbits (2.5-3.0 kg) from Cheshire Rabbit Farms Ltd. The 
animals were housed individually and allowed free access to 
water and food ad libitum.
7.2.1 In vivo infusion.
Groups of rabbits received guanabenz acetate dissolved 
in 40% alcohol and 60% 0.1% ascorbate at a concentration of
50 mg/ml. The drug was infused via a minipump implanted as 
described in the methods section 2.2.2.2 for 5 days at the 
rate of 237 ug/kg/hr. Control groups received vehicle. In 
acute studies the drug was infused into a peripheral ear 
vein at the same rate for 5 hours.
7.2.2 Pressor responses to alpha-methylnoradrenaline.
Dose-response curves were constructed for bolus 
injection of alpha-methylnoradrenaline 5 - 100 ug in both 
control and guanabenz (acute and chronic) treated groups. 
The dose required to increase the mean arterial pressure 
(MAP) by 50 mmHg in individual animals was obtained from 
the curves. The intravenous line for injection of drugs and 
the arterial lines for measurement of blood pressure were 
inserted under local anaesthesia as described in the methods 
section 2.1. In the acute studies pressor dose response 
curves were constructed before and after 5 hours infusion of
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guanabenz, thus in these experiments the animals acted as 
their own controls.
7.2.3 Intracisternal injection of clonidine.
The effects of chronic guanabenz infusion on the 
depressor response to clonidine injected intracisternally, 
was studied at the end of 5 days infusion. Rabbits were 
anaesthesized with pentobarbitone sodium (30-60 mg/kg) and 
clonidine 1 ug/kg was injected into the cisterna magna by a 
free hand transcutaneous injection in a total volume of 1 0 0  
ul (Chalmers and Wurtman, 1971). Blood pressure and heart 
rate changes were monitored continously for 5 minutes and 
then every 15 minutes thereafter for 60 minutes.
7.2.4 Tissue preparation.
At the end of the experiments, rabbits were killed by 
an overdose of pentobarbitone sodium (i.v). The brain and 
kidney were removed, placed on ice and cleansed of blood and 
conective tissue. The brain tissue was then dissected into 
forebrain and hindbrain at the point of colliculli. The 
tissues were prepared by homogenization and centrifugation 
as described in the methods section 2.4.1.
7.2.5 Radioligand binding assays.
Radioligand binding assays were performed on tissue 
homogenates using [ ] yohimbine (1.25 - 37.5 nM) and
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•3
[ H]idazoxan (0.5 - 20.0 nM). Incubations were carried out as 
described in section 2.4.2. The radioactivity was counted 
using a Packard Tri-Cab Model 3255 liquid scintillation 
counter at an efficiency of 36%.
7.2.6 Data analysis.
The binding parameters were,obtained from modified 
Scatchard plot analysis as described in section 2.4.3. Data 
generated from analysis of Scatchard plots (Bmax and KD ) 
were subjected to unpaired t-tests. To compare responses to 
alpha-methylnoradrenaline in treated and control animals, 
pressor dose-response curves were constructed in individual 
animals and the dose required to raise mean arterial 
pressure by 50 mmHg calculated. The differences between the 
groups was tested using unpaired t-test. The depressor 
response after clonidine injection was analysed by analysis 
of covariance using the package Rummage (Bryce, 1980) run 
on an ICL 2988 mainframe computer. The preinjection blood 
pressure was used as covariant.
7.3 RESULTS.
There were no significant changes in blood pressure or 
heart rate throughout the period of drug infusion. The blood 
pressure was 9 0 + 9  for control and 80 + 10 m m H g  for 
guanabenz treated animals. No obvious behavioural changes 
were observed.
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7.3.1 E f f e c t s  c> f b o l u s  d o s e s  c>f^  i i P M l  
methylnoradrenaline.
The effect of treatment with guanabenz on pressor 
responses i n d u c e d  b y  b o l u s  d o s e s  of a l p h a -  
methylnoradrenaline was exa m i n e d  by comparing the dose 
required to increase the mean arterial blood pressure by 50 
mmHg. The dose required to increase the blood pressure by 50 
mmHg was shown to be significantly (p < 0.01) increased to 
63 _+ 10 ug for chronically treated animals from 20 5 ug in
control animals when responses in individual animals were 
compared. The treatment with guanabenz shifted the dose- 
response curve rightwards with a dose ratio of 3 (figure 
7.1) when pooled data from guanabenz treated and control 
rabbits were compared. Acute infusions of guanabenz (5 
hours) had no effect on pressor responses to alpha- 
methylanoradrenaline bolus doses.
7.3.2 Effects of intracisternal clonidine injection.
The response to intracisternal clonidine (1 ug/kg) 
injection was attenuated by 5 days of guanabenz infusion. 
The maximum fall in blood pressure was observed at 5 minutes 
after injection for the guanabenz' treated group (-14 +_ 10 
mmHg) and at 15 minutes (-26 + 15 mmHg) for the control 
group. The fall in blood pressure was significantly (p < 
0.05) attenuated at 5, 15, 30, and 45 minutes after
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injection in the guanabenz treated group (figure 7.2). There 
was no significant treatment effect on the heart rate.
o o
7.3.3 [JH]Yohimbine and [JH]idazoxan binding sites.
Five days guanabenz infusion significantly reduced the 
number of [^H]yohimbine binding sites (Bmax) in both the 
forebrain and hindbrain by 47% and 45%, respectively (p < 
0.003 and p < 0.02). Yohimbine binding sites in the kidney 
were not significantly affected by this treatment (figure 
7.3). The dissociation constant (KD) was not affected by five 
days guanabenz treatment in any tissue studied (Table 7.1). 
In contrast, 5 days of guanabenz treatment significantly (p 
< 0.002) decreased [ H]idazoxan binding sites in the kidney 
by 41%, but no significant treatment effect on Bmax was 
observed in the forebrain or hindbrain (figure 7.4). 
However, the KD of [^H]idazoxan for the binding site was 
significantly (p < 0.03) increased (KD : 3  + 2  and 6 + 3 nM) 
in the hindbrain as a result of this treatment. No change in 
affinity constants were observed in either the forebrain or 
the kidney (table 7.1).
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Figure 7.1
Effects of chronic guanabenz (237 ug/kg/hr) infusion on 
pressor r e s p o n s e s  to b o l u s  d o s e s  of a l p h a -  
methylnoradrenaline .
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Effects of chronic guanabenz (237 ug/kg/hr) infusion on the
depressor response to clonidine ( 1 ug/kg) injection (i.c).
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Effects of chronic guanabenz (237 ug/kg/hr) infusion on the 
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TABLE 7.1
Effects of chronic guanabenz infusion on dissociation constants 
(Kd nM).
[^H]Yohimbine [^H]Idazoxan
forebrain hindbrain kidney forebrain hindbrain kidney 
Control 8 + 2 1 1 + 6  7 + 4 4 + 2  3 + 2  4 + 3
Guanabenz 10 4 13 _+ 5 11 + 4 7 ^ + 4  6 _+ 3* 5 _+ 3
Results: mean + S.D, n = 6 - 9, * p < 0.05.
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7.4 DISCUSSION.
Many excitable cells exhibit homeostatic mechanisms 
that change their responsiveness to stimulation when neural 
inputs are altered. Prolonged exposure to drugs or hormones 
may result in an attenuation of the physiological response 
(Trendeleburg, 1 9 63; Harden, 1 983; Hayes et al., 1 984). 
Although this has been most extensively studied for beta- 
adrenoceptors (Lefkowitz et al., 1983; Toews and Perkins, 
1984; Strasser et al., 1985), it has also been examined for 
alpha-adrenoceptors (Majewski and Story, 197 6 ; Brodde et 
al., 1982; Maura et al., 1985; Jones et al., 1986). 
Prolonged exposure of receptors to agonists may lead to 
loss of receptor number in addition to desensitization. This 
has also been described in many tissues (Catt et al., 1979; 
Davies and Lefkowitz, 1981; Finberg, 1987) and cell 
preparations (Remold-O'Donnell, 1974; Sabol and Nirenberg, 
1979; Brodde et al., 1982; Hamilton et al., 1987) for alpha- 
adrenoceptors .
Clonidine and guanabenz have been reported to act by 
activating central and peripheral alpha2 _adrenoceptors which 
leads to reductions in catecholamine turnover and hence 
reduced sympathetic outflow (Haeusler, 1974; van Zwieten, 
1975; Kobinger, 1978; Meachen et al., 1980; Misu and Kubo,
1982) . In addition, prolonged activation of this receptor 
may result in desensitization (Brodde et al., 1982; Engberg 
et al., 1982; Maura et al., 1985; Finberg and Kopin, 1987). 
It has been postulated that the withdrawal syndrome observed 
after cessation of clonidine and guanabenz treatment could
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be related to desensitization and down-regulation of central 
alpha2-adrenoceptors (Paker and Atkinson, 1982/ Conway and 
Jarrott, 1982; Finberg and Kopin, 1987). However, down- 
regulation on chronic clonidine treatment has only been 
convincingly shown in hypertensive rats (Armstrong et al.,
1983) .
In these experiments, chronic infusion with guanabenz 
attenuated the pressor response to bolus doses of alpha- 
methylnoradrenaline. The observed desensitization of the 
pressor response to the alpha2-adrenoceptor selective 
agonist alpha-methylnoradrenaline after chronic guanabenz is 
consistent with the peripheral alpha2_adrenoceptor agonist 
properties of this drug (Gutkin et al., 1986) and with the 
observations of reduced sensitivity of alpha2~adrenoceptors 
after chronic treatment with other alpha2-adrenoceptor 
agonists (Takeyaku et al., 1982; Ishii and Koto, 1984; 
Deighton et al., 1986; Jones et al., 1986; Hamilton et al.,
1987) . The depressor response induced by intracisternal 
injection of clonidine was also significantly attenuated by 
chronic guanabenz infusion. Consistent with this finding is 
the observed desensitization of central alpha2~adrenoceptor 
mediated responses after chronic treatment with other
alpha2_agonists (Maura et al., 1985; Raiteria et al., 1986;
Finberg and Kopin, 1987).
*3 , ,
Decreases in [ JH]yohimbine binding sites in the 
hindbrain were observed and are consistent with the
attenuation of the depress or  response induced by
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intracisternal clonidine injection. Decreases in receptor 
number were also observed in the forebrain but with no 
change m  the kidney. The lack of change m  [ JH] yohimbine 
binding to the kidney may possibly be due to differences in 
guanabenz concentration at this site and in the brain. In 
addition, subtypes of alpha2 ~adrenoceptor predominating in 
different tissues may be a contributory factor to the 
localized changes in receptor density observed in this 
study. Localized changes in receptor number have also been 
reported after chronic treatment with other drugs (Minneman 
1983; Winter et al., 1986).
A d i f f e r e n t  p a t t e r n  of d o w n  r e g u l a t i o n  for 
[^H]idazoxan binding sites with no change in brain but down 
regulation in the kidney was observed after chronic 
guanabenz infusion. Differential regulation of idazoxan and 
yohimbine binding sites supports the hypothesis that the two 
ligands bind to distincts sites. Guanabenz appears to have 
an affinity for both binding sites (yohimine and idazoxan) 
and to regulate them independently.
In conclusion, chronic guanabenz infusion significantly 
attenuated both peripheral and central alpha2 -adrenoceptor 
mediated functions. The density of [ H ] y o h i m b i n e  and 
[^H] idazoxan binding sites in brain and kidney membranes 
were differentially regulated which further shows that both 
ligands bind to different entities in the brain and kidney
•3
membranes. In addition, the changes m  [ JH]yohimbine 
observed in the brain could help explain the mechanism 
behind withdrawal reactions reported after sudden
177
withdrawal of centrally acting drugs.
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CHAPTER EIGHT 
GENERAL SUMMARY, DISCUSSIONS AND CONCLUSION.
This chapter is intended to bring all the results in 
this thesis together, discuss them and suggest directions 
for future studies.
Activation of p e r i p h e r a l  b l o o d  v e s s e l  a l p h a 2 - 
adrenoceptors has been shown to cause vasoconstrict ion 
leading to increased blood pressure while central 
adrenoceptor stimulation causes reduced sympathetic tone and 
a reduction in blood pressure. These functions have been 
used to study effects of adrenoceptor drugs on alpha 2 ~ 
receptor sensitivity (Hannah et al., 1983; Hamilton and 
Reid, 1985; Hamilton et al., 1986; Deighton et al., 1988). 
Bolus doses of alpha-methylnoradrenaline and intracisternal 
injection of clonidine were used to study effects of acute 
and chronic treatments with adrenoceptor drugs on peripheral 
and central alpha 2 _receptor responsiveness respectively. 
Chronic treatment with the antagonists idazoxan and 
yohimbine attenuated both pressor and depressor responses to 
alpha-methylnoradrenaline and intracisternal clonidine 
injection. Acute and chronic treatment with idazoxan caused 
a similar attenuation of responses. Thus these studies did 
not show any changes in responses during chronic drug 
treatment with antagonists. In contrast, differences were 
observed between acute and chronic treatment with agonists: 
chronic but not acute treatment with guanabenz attenuated 
both depressor and pressor responses induced by clonidine 
and alpha-methylnoradrenaline  injections, while the
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depressor response to clonidine injection was significantly 
attenuated by intracerebroventricular adrenaline but not 
noradrenaline infusion (Table 8.1). Attenuation of responses 
during agonist treatment is consistent with receptor 
desensitization and down-regulation. These observations are 
also c o n s i s t e n t  w i t h  p r e v i o u s  s t u d i e s  in w h i c h  
desensitization of peripheral alpha 2 -adrenoceptors were 
observed during agonist infusion (Hamilton et al., 1987; 
Deighton et al., 1988). The inability of noradrenaline to 
influence the central alpha2 ~adrenoceptors mediated function 
may have been related to the low levels of noradrenaline 
achieved in hindbrain during infusion. It may also be 
related to noradrenaline's selectivity and potency at the 
alpha2 ~adrenoceptor. Adrenaline has been shown to be a more 
potent agonist at alpha 2 -adrenoceptors than noradrenaline. 
In addition, the subtype of alpha2 ~receptor predominating in 
the region of the brain examined may account for this 
discrepancy (Petrash and Bylund 1986; Bylund 1988; Reid et 
al., 1988). In the periphery, different effects of 
adrenaline and noradrenaline on platelet and kidney alpha2 ” 
adrenoceptors have been reported (Deighton et al., 1988a,b) 
which are consistent with the differences in subtypes of 
alpha2 -receptors identified in these tissues. Table 8.1 
presents a summary of functional changes observed in these 
studies during chronic drug treatment.
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TABLE 8.1
SUMMARY OF FUNCTIONAL CHANGES AS A RESULT OF CHRONIC DRUG TREATMENTS.
Alpha-MeNA injection (iv) Clonidine injection (ic)
(pressor effect) (depressor effect)
Treatments:
Antagonists:-
Idazoxan:-
acute
0.56 & 1.1 mg/kg/hr
attenuated
chronic 
1.1 mg/kg/hr
attenuated attenuated
Yohimbine 
15 mg/kg/day
attenuated attenuated
Agonists
Adrenaline 
100 ug/kg/hr
attenuated
Noradrenaline 
150 ug/kg/hr
No significant 
effect
Guanabenz 
237 ug/kg/hr attenuated attenuated
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In radioligand binding studies [ H]yohimbine has been 
shown to label alpha 2 ~adrenoceptors with high affinity 
(Motulsky et al., 1 980; Bylund, 1981; 1 985). Chronic
treatment with yohimbine and idazoxan significantly increased 
[H] yohimbine binding sites in the forebrain but not in the 
hindbrain; an increase in [^H]yohimbine binding in the kidney 
was also observed with yohimbine but not with idazoxan
treatment. Agonist treatment with guanabenz significantly
3 . . .reduced [ H]yohimbine binding to both forebrain and hindbrain
while a m i t r i p t y l i n e  w h i c h  m a y  c a u s e  i n c r e a s e s  in
catecholamine concentrations in the brain significantly
reduced the number of binding sites in the hindbrain. These
changes in binding sites are consistent with changes
occurring at receptor sites after chronic agonist or
antagonist treatment, with antagonists causing up-regulation
and agonists down-regulation. The changes in receptor number
observed in these studies in the hindbrain are consistent
with the changes observed in response to intracisternally
administered clonidine. Amitriptyline which down-regulated
[^H] yohimbine binding has previously been shown to cause
attenuation of the depressor response to clonidine (Hamilton
et al., 1986). Similarly guanabenz caused down-regulation in
both [ ^ H] yohimbine binding in the hindbrain and in the
response to intracisternally a d ministered clonidine
injection. In contrast, treatment with the antagonists
idazoxan and yohimbine caused an up-regulation of receptor
number in forebrain but no changes in the hindbrain and no
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evidence for altered depressor responses to clonidine were 
observed during chronic treatment with these drugs. Chronic 
adrenaline and noradrenaline had no significant treatment 
effects on [JH]yohimbine binding sites, although adrenaline 
infusion attenuated responses to intracisternal clonidine 
injection. However, desensitization of functional responses 
frequently precedes down-regulation in receptor number and it 
has been shown that treatment with low doses of amitriptyline 
may cause attenuation of responses to clonidine without any 
concomitant decrease m  [^H]yohimbine binding.
Differences in regulation in different brain regions 
have been observed. This may be due to differences in drug 
concentrations in different brain areas. Adrenaline and 
noradrenaline were infused into the brain and much higher 
concentrations of catecholamine were observed in the 
forebrain than in the hindbrain; amitriptyline is assumed to 
cause increases in biogenic amines including adrenaline and 
noradrenaline concentrations in the brain synapses via uptake 
blockade and may cause higher concentrations of these amines 
in the hindbrain. In addition, the density of innervation of 
different brain regions may account for these localized 
changes. Furthermore, drug concentrations could be 
selectively elevated in the regions with high receptor 
density or innervation. Finally, subtypes of a l pha 2 ~ 
adrenoceptor p r e d o minating in different brain regions 
(Petrash and Bylund, 1986; Bylund, 1988) could contribute to 
the differential regulation of receptors in different areas 
and tissues. Table 8.2 presents s ummary of receptor
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regulation observed with adrenoceptor drug treatments in 
these studies.
In contrast, to alpha 2 _adrenoceptor binding, beta- 
adrenoceptor binding sites in the brain as identified by 
[ H]dihydroalprenolol were not significantly affected by the 
drug treatments examined in this thesis (Table 8.2). However 
changes in the periphery have been observed (Tsujimoto and 
Hoffman, 1985; Deighton et al., 1988; Elfellah et al., 1988). 
The lack of change in beta-adrenoceptor number in rabbit 
brain contrasts with changes observed in rat brain after 
chronic treatment (Bergstrom and Kellar, 1979; Minneman e t s 
al., 1982; Sugrue, 1983; Toews and Perkins, 1984; Beer et 
al., 1986). It is however possible that subtype selective 
changes might have occurred. Dihydroalprenolol is a non- 
selective drug and small changes in beta-^- or beta2 - subtypes 
might not have been detected. Alternatively, beta- 
adrenoceptors in rabbit brain may be more resistant to 
agonist regulation.
During p r e l iminary studies, it was observed that 
3 3[ Hjidazoxan and [ H] yohimbine which have been defined as 
typical alpha 2 ~adrenoceptor ligands (Cheung et al., 1982; 
Motulsky et al., 1980; Convents et al, 1987; Ruffolo et al., 
1988) did not bind to rabbit brain or kidney membranes with 
similar characteristics. This observation led to the 
displacement studies described in chapter three using 
various adrenoceptor drugs to displace these ligands from 
their binding sites. It was observed in these experiments
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TABLE 8.2
SUMMARY OF RECEPTOR REGULATION AS A RESULT OF DRUG TREATMENTS.
[3H]Yohimbine
“3
[JH]Idazoxan [3H]DHA
FB HB KID FB HB KID FB HB
Idaz UP NC NC NC NC DOWN
Yoh UP NC UP NC NC DOWN _
Amit NC DOWN NC NC _ NC NC
Amit + Yoh NC NC NC NC _ NC NC
Amit + Idaz NC NC NC NC NC NC
Adr NC NC _ DOWN ? NC _ .
Norad NC NC NC NC _ NC NC
Gbz DOWN DOWN NC NC NC DOWN NC NC
FB = forebrain, HB = hindbrain, KID = kidney, A m i t  = 
amitriptyline, Yoh = yohimbine, Idaz = idazoxan, Adr = 
adrenaline, Norad = noradrenaline, Gbz = guanabenz, DOWN = 
reduction in receptor number, UP = increase in receptor number, 
NC = No change, ? = Reduction in the right cerebrum, - = Not 
studied.
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that [H]yohimbine bound principally to alpha2 ~adrenoceptors 
and was displaced from this site with high affinity by
*3
alpha2 _adrenoceptor drugs, while [ H] idazoxan was not 
displaced by typical adrenergic drugs such as adrenaline and 
noradrenaline but was displaced by drugs with imidazol(in) e 
or related structures with high affinity. These observations 
have been confirmed by others (Boyajian et al., 1987; 
Lachaud et al., 1987; Bricca et al., 1988; Wikberg 1988; 
Yablonsky et al., 1988; Vigne et al., 1989).
In addition, these ligands labelled different 
populations of binding sites in both the brain and the 
kidney, with more [ H] yohimbine binding m  the brain and more 
[^H]idazoxan binding in the kidney. These observations were 
followed up by looking at the effects of chronic drug 
treatments on the [ H] idazoxan binding site and comparing
•3
with effects on the [H]yohimbine binding site. In the in 
vivo studies in which animals were treated chronically with 
alpha2 _adrenoceptor drugs, the idazoxan binding site was 
regulated independently of the yohimbine binding site. The 
idazoxan binding sites in the brain were not significantly 
affected by any of the chronic drug treatments except 
adrenaline which significantly reduced binding to the right 
cerebrum. However, in the kidney, chronic guanabenz infusion 
significantly reduced the number of idazoxan binding sites, 
while chronic treatment with the a l p h a 2 -adrenoceptor 
antagonists yohimbine and idazoxan^ also significantly down- 
regulated this site. These effects on the number of idazoxan
187
binding sites did not conform with the antagonist properties 
of these drugs. The changes observed with yohimbine were 
surprising since yohimbine only displaced [ H]idazoxan in the 
in vitro displacement experiments with low affinity (in 
micromolar range). Thus this effect may be an indirect 
effect, and a decrease in the KD was observed along with the 
reduction in number. It is possible that yohimbine and 
idazoxan might be acting as agonists on this binding site. 
Alternatively the reduction in binding sites may be related 
to the Na+/K+ antiportes, since the Na+/K+ blocker amiloride 
has been reported to displace [H]idazoxan from its binding 
sites in rabbit adipocyte membranes with high affinity 
(Langin and Lafontan, 1989). However, this might not be the 
case since amiloride has also been reported to be a 
promiscuous drug that binds with -micromolar affinities to 
many other receptors including adrenergic receptors (Howard 
et al., 1987) .
In conclusion, regulation of alpha2 _adrenoceptors in the 
central nervous system by agonists and antagonists is 
consistent with current concepts of agonist down-regulation 
and antagonist up-regulation of receptors. These changes were 
accompanied by functional regulation. Differences between the 
regulation of alpha2 ~receptors in the brain and the periphery 
have been observed. In addition, differences between brain 
regions were also observed and this may be due to the 
predominance of different subtypes of receptors in different 
regions. The newly labelled idazoxan binding site has been 
shown to be distinct from the alpha 2 ~adrenoceptor binding
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site. The nature and integrity of this binding site is not 
yet fully known, but it appears to be resistant to drug 
regulation in the brain. For further insights into the 
properties of this binding site an extensive study is 
required looking at the nature of the second messenger to 
which this site is coupled. In addition, the function of this 
site requires to be elucidated. It is possible that the 
idazoxan site may have functions which have previously been 
attributed to alpha2 ~adrenoceptors. Such studies will further 
the understanding of the nature of the central nervous system 
and peripheral receptors and help to unravel the complex 
pharmacology of alpha-adrenergic receptors.
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